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ABSTRACT
AN IMPLANTABLE DRUG DELIVERY CONCEPT IN CANCER
CHEMOPREVENTION

Shyam Sunder Bansal
August 08, 2011
Curcumin, a plant derived compound has shown significant potency against various
chronic diseases like cancer in cell culture and animal studies. However, the introduction
of this compound into clinical setting is limited by its poor oral bioavailability and thereby
requires high doses for efficacy. We hypothesized that localized/systemic delivery of
curcumin by polymeric implants can improve its efficacy by bypassing the oral route and
by restricting majority of the drug at the tumor site. Therefore, we developed a polymeric
implantable drug delivery system using poly (E-caprolactone) as the polymer and
optimized it with respect to polymer molecular weight, drug load and formulation
additives both under in vitro as well as under in vivo conditions so as to obtain a desired
drug release profile.

Drug release was found to be proportional to surface area and drug load for up to 10%
concentration. The presence of water-soluble polymers like polyethylene glycol (PEG) at
35% w/w composition was also found to increase the drug release with in vivo release
being 1.8-2 fold higher than in vitro release. Higher plasma and brain curcumin
concentrations with almost similar levels in liver were observed by these implants but at
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25-30 fold lower doses than dietary curcumin even after 3 months. Furthermore, these
implants were found to provide a controlled/predictable release ranging from months to
years.

Analysis of biochemical parameters of liver and kidney function revealed non-toxicity of
the implant formulation as well as of curcumin administered continuously into systemic
circulation by these implants. Although a mild to moderate inflammatory reaction was
observed at the local site of implantation, yet no toxic effect on health or physical well
being of rats was observed. Moreover, systemically administered high doses of curcumin
(by implants) were found to be more efficacious in modulation of cytochrome P450
enzymes like CYP1A1, CYP3A4 and CYP1B1 as well as in inhibiting Ermediated
mammary tumorigenesis in ACI rats. These implants were found to reduce the tumor
burden significantly by 35% and tumor multiplicity by 70% via favorable alteration of E2
metabolism suggestive of curcumin's potent chemopreventive activity when delivered via
implants as compared to diet.
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CHAPTER I
INTRODUCTION

Breast cancer is the second leading cause of cancer deaths in US and accounts for 15%
of all cancer deaths. It is estimated that 1 in 8 women in the United States will develop
breast cancer in their life time and 1 in 30 will die from it. Statistics further showed that
breast cancer death rates remained almost constant from 1930 to 1990 and decreased
by 29% in 1990 to 2006 (American Cancer Society) (1). This decrease in breast cancer
incidence was due to the advancements in breast cancer screening and treatment
strategies. Currently, surgery, radiation and systemic therapy with chemotherapeutic
agents are the most widely used approaches for breast cancer treatment. Surgery and
radiation are undesirable by women due to obvious reasons and it is only the systemic
therapy that provides few alternative treatment regimens for breast cancer. Systemic
therapy involves use of biologics like trastuzumab (her2/neu monoclonal antibodies),
chemotherapy (with paclitaxel, docetaxel), hormone therapy (with tamoxifen) for
estrogen receptor-positive breast tumors or metronomic chemotherapy involving low,
less toxic doses of anti-angiogenic agents (2).

However, the use of these regimens is limited either due to their low bioavailability, high
toxicity, significant first-pass metabolism, high doses and/or poor patient compliance.
Due to these limitations other safe drugs or therapeutic regimens are often desired (2).

1

Since a typical

carcinogenesis process involves many environmental, dietary,

occupational, and epigenetic factors that determine its long latent period; intervention
with phytochemicals that have little or no toxicity can provide an alternative strategy for
controlling the initiation and progression of this disease. As a result, studies initiated by
the National Cancer Institute have led to the screening and identification of thousands of
natural compounds, of which a few dozen (like curcumin, resveratrol, epigallocatechin
gallate (EGCG), ellagic acid, quercetin, and indole-3-carbinol) exhibited potent
chemopreventive/anti-tumor activity in cell-culture as well as in some animal studies.
These agents were found to block the cancer progression by affecting all the stages of
carcinogenesis, including transformation, proliferation and invasion of tumor cells. Their
long-term use in folklore medicines from historic times further demonstrate their safety
profile and their potential for long-term use in normal as well as high-risk populations (3).
These chemopreventives are widely distributed in almost all the colored fruits and
vegetables and

~5

servings of fruits and vegetables per day are recommended by

American Cancer Society for their chemoprevention efficacy against various diseases,
including cancer (1). However, less than 1 in 4 American adults eat the recommended
servings and there has been very little improvement in the consumption of fruits and
vegetables since 1990s (American Cancer Society) (1). Therefore, other alternative
means are required for the administration of active chemopreventive compounds and
their usage in day to day life.

2.0. Curcumin: A Potent Chemopreventive

Although, a number of potent chemopreventives have been identified from plant
sources, curcumin, a principal bioactive component of Curcuma longa (turmeric),
represents one of the most investigated phytochemicals. Pubmed shows -4000 hits on
using curcumin as the search string with -1200 hits from last 2 years alone. There are 3

2

major

curcuminoids

that

constitute

curcumin:

curcumin

(curcumin

I,

75%),

demethoxycurcumin (curcumin II, 20%) and bisdemethoxycurcumin (curcumin III, 5%)
(Figure 1.1). Research over last two decades has shown curcumin to be a potent antioxidant,

anti-inflammatory,

anti-proliferative,

anti metastatic,

anti-angiogenic,

anti-

diabetic, hepatoprotective, anti-atherosclerotic, anti-thrombotic, and anti-arthritic agent
(4, 5). Various cell culture studies have shown that it inhibits various protein kinases (like
EGFR, IKK, JAK2, PKC, PKA), transcription factors (like NF-kB, AP-1, STAT, PPARy)
and enzymes (like GST, hemoxygenase, xanthine oxidase) and various others (Figure
1.2) (4-7) responsible for its variety of potent activities. However, 3 main mechanisms
have been postulated to be responsible for curcumin's anticancer/chemopreventive
activities.
(i)

Modulation of hepatic cytochromes (8).

(ii)

Induction of antioxidant response pathways (9).

(iii)

Inhibition of NF-kB activation (6, 10).
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Figure 1.1. Structures of curcuminoids.
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Figure 1.2. Various intracellular signaling molecules affected by curcumin (5) .

2.1.1. Modulation of Hepatic Cytochrome P450s

Curcumin is well known for its potential to inhibit carcinogenesis induced by chemical
carcinogens, at both initiation and progression stages by altering various xenobiotic
metabolizing enzymes in the liver (11). It has been found to interact with pregnane X
receptor (PXR) to induce expression of CYP3A4 by which not only it alters the
metabolism of various other xenobiotics but also induces its own metabolism in
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conjunction with UGT (12). It is also both an inducer as well as a competitive inhibitor of
CYP1 A 1 inhibiting bioactivation of environmental carcinogens like benzo[ajpyrene
(B[ajP) (13). It is a potent ligand to aromatic hydrocarbon receptor (AhR) and interacts
with it in the cytoplasm (Figure 1.3). AhR exists in cytosol in complex with heat shock
protein 90 (hsp90) and gets activated on interacting with curcumin like ligands. Liganded
AhR then translocates into the nucleus and interacts with AhR nuclear translocater
(ARNT) . The complex then interacts with the xenobiotic response elements (XRE) or
dioxin response elements (OREs) to initiate the expression of CYP P4501A1 genes (14).

CYTOPLASM

~SP90

_

_-

NUCLEUS J;.ANT

AhA s

~ ~

~

..

I

'-...J~
· sp90
AhA
9

~(ARNi)

~

(@5 ....

••••••

mRNA

TRANSLOCATION
Cytochrome P-4501 A1
induction

Figure 1.3. Schematic overview of CYP 1A 1 induction by curcumin via AhR pathway

2.1.2. Activation of Nrf2 Pathway
Curcumin is also a potent inducer of endogenous antioxidants via activation of Nrf2
pathway to strengthen body's defenses against reactive oxygen species (ROS) (11)
(Figure 1.4). Expression of endogenous antioxidants, like GSH , is controlled by NF-E2related factors 1 and 2 (Nrf1 and Nrf2) that bind to antioxidant response elements
(AREs) and activate various genes. The activity of Nrf2 is controlled by inhibitory effects

5

of a cytoskeletal protein keap1 and the complex exists in an inactive form in the cytosol.
In conditions of environmental stress, cigarette smoke, reactive oxygen species or
metals, Nrf2 gets phosphorylated which then translocates into the nucleus. In the
nucleus, Nrf2 in association with bZIP family of transcription factors interacts with AREs
to induce expression of endogenous antioxidants, xenobiotic-detoxification enzymes,
transporters and proteasomes (9).
CurcuminlEnvironmental stress
(Cigarette smoke, Electrophiles, Metals, ROS , NO, Endotoxin)

Proteasomal
degradation
./ Induction of Endogenous Antioxidants
./ Xenobiotic detoxification enzymes
./ T ransporters
./ Proteasomes

Figure 1.4. Schematic overview of Nrf2 pathway activation by curcumin

2.1.3. Blockade of NF-kB Pathway

Curcumin's potent anti-inflammatory activity has been shown to be due to the inhibition
of IKB kinase required for the activation of NF-kB, an important transcriptional regulator
of inflammatory pathways involved in carcinogenesis and various other pathological
conditions (6, 10) (Figure 1.5). NF-kB belongs to a family of 'rapid acting' primary
transactivation factors that regulate various inflammatory and immune responses in the
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body. NF-kB exists as an inactive heterodimer or homodimer of p50, p52 or p65
sequestered with Inhibitory kB protein (lkBs). Phosphorylation and subsequent
degradation of IkB by IkB kinase result in the activation of NF-kB which then translocates
into the nucleus to initiate transcription of various genes regulated by it. Curcumin has
been found to be a potent inhibitor of IkB kinase and hence inhibits the activation of NFkB in response to various inflammatory stimuli. Since NF-kB plays an important role in
the initiation and progression of carcinogenesis, its inhibition by compounds like
curcumin has been postulated to be one of the important mechanisms of its anticancer
activity (15).
INFLAMMATORY STIMULI

1

CURCUMIN

IKB kinase

•

:':-~!~~~ ~::;

Inflammatory/Immune
Proteins

Degradation

CYTOPLASM

Fig. 1.5. Schematic overview of curcumin mediated NF-KB inactivation via inhibition of IKB kinase

2.2. Physico-chemical Properties of Curcumin
Curcumin is a yellow-orange crystalline powder first isolated in 1815 from rhizomes of
Curcuma tonga (turmeric). Its structure was deduced in 1910 by Lampe et al. and was

confirmed by synthesis in 1913 by lampe and Milobedzska (16). It melts at 180-183 DC
and is practically insoluble in water but soluble in ethanol , dimethylacetamide,
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dimethylsulfoxide and acetone (17). It exhibits a brilliant yellow hue at pH 2.5-7 and red
at alkaline pH (17). Depending upon the solvent used, it absorbs at 420-430 nm in
visible region and exhibits three acidity constants viz pKa1
and pKa3

= 10.51 ±0.01

=8.38±0.04, pKa2 =9.88±0.02

(18). Chemically, it is bis-a,j3-unsaturated j3-diketone and exists

in equilibrium with its enol tautomeric form (Figure 1.). In acidic and neutral aqueous
solutions bis keto form, a H-atom donor, is predominant while basic solutions shift the
equilibrium towards enolate anion which acts as a strong e- donor at basic pH (17). In
acidic/neutral conditions, the e- density of two adjacent -C=O oxygens get localized and
the C-H bonds in central -CH2 group in hepta-di-ene chain becomes very weak. These
labile hydrogens can then react with other radicals to exert an antioxidant activity.
However, at pH>8, due to enolate form, the reaction with the free radical blunts and the
phenolic part acts as an e- donor that can scavenge alkyl phenoxy radicals. Hence, this
keto-enol tautomerism confers curcumin with its free radical-scavenging activity which is
further substantiated by intermolecular H bonding predominant in its enolate form (19).
Furthermore, it is reported that potent antioxidant activity of curcumin is conferred by its
two terminal methoxy phenol groups (19). However, empirical linear energy relations
showed oxidation potential of curcumin to be 0.77V which is considerably higher than
other potent phenol group containing antioxidants like vitamin E (-0.48V), vitamin C
(-0.28V), methyl gallate (-0.52V) or quercetin (-0.33V) (19). According to Jovanovic et
aI., curcumin's potent antioxidant properties might not only be due to its methoxy phenol
groups and other structural features, like keto-enol tautomerism, also contribute
significantly (19). Furthermore, hydroxyl groups on the aromatic rings and the diketone
functionality both are required structural features for the induction of phase II detoxifying
enzymes (20). However, curcumin is also highly unstable at basic pH and -90%
degrades within 30 mins to form trans-6-(4'-hydroxy-3'-methoxy phenyl)-2,4-dioxo-5hexanal, vanillin, ferulic acid and feruloyl methane (21). But its stability increases on
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supplementing the basic solutions with albumin or with blood/plasma and in presence of
antioxidants such as ascorbic acid, N-acetylcysteine or glutathione (22).

2.3. Curcumin Pharmacokinetics
Although the structural attributes of curcumin make it a potent anti-oxidant, they also
render it poorly water soluble. As a consequence, it exhibits solubility-limited
bioavailability, which makes it a class II drug in the Biopharmaceutical Classification
System (BCS) (23). Furthermore, due to its rapid intestinal and hepatic metabolism,
approximately 60-70% of an oral dose of curcumin gets eliminated in the feces (22). In
both pre-clinical as well as clinical studies, even high doses of orally-administered
curcumin (8-12 g daily) resulted in very low concentrations in the plasma levels «1
Ilg/ml) that were not high enough to exert any significant pharmacological or therapeutic
activity (table 1.1) (24). In rats, curcumin administered as an aqueous suspension
(2g/kg) provided a maximum plasma concentration of 1 Ilg/ml within 1 h, and dropped
rapidly to undetectable levels within 5 h (25).

When curcumin was administered by

parenteral routes like Lv., -50% was found to be eliminated in bile within 5 h. It has
been found that curcumin undergoes rapid metabolism in the liver to form various active
and inactive metabolic products that are further converted into excretable glucuronide
and sulfate conjugates. Curcumin provides easily accessible phenolic -OH and -OCH3
sites (Figure 1.1) to form conjugates with glucuronides and sulfates that can be
deconjugated by glucuronidases and sulfatases, respectively (12). It has been
suggested that this biotransformation of curcumin occurs during absorption or by firstpass metabolism which then undergoes enterohepatic recirculation (26). These results
were further supported by Shoba et al (25), who showed that co-administration of
piperine (20 mg/kg), a potent inhibitor of glucuronidation in the liver and gastro-intestinal
tract, significantly increased the curcumin bioavailability by 20 fold in humans.
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Table 1.1
Examples of some pre-clinical (A) and clinical (8) studies reported with curcumin.
A: Preclinical Studies

Animal
Rats

Route
oral

Dose
19/kg

Rats

oral

2% diet

Mice

i/p

100 mg/kg

Rats

i/v

40 mg/kg

Findings
• Poorly absorbed
• 75% excreted in feces
• 12 nM in plasma

Refs.
(27)

• 2.25 I1g/ml in 15 mins
• Disappeared within 3h
• Disappeared within 1 h

(22)

(28)

(29)

B: Clinical Studies

Route
Oral
(n=34*)

Oral
(n=21 *)

Oral
(n=25*)
Oral
(n=12*)

Findings
• No reduction in peripheral biomarkers of
inflammation
improvement
in
cognitive
• No
performance in alzheimer's patients.
8 g/day until disease
• 1 patient showed stable disease «18
progression
months) and one showed tumor
regression with an increase in serum
cytokines 22-41 ng/ml peak plasma
levels
8 g/day for 3 months • -1.77 11M plasma conc. Peaked at 1-2 h
and declined within 12 h
450-3,600 mg/day
• Poorly available, insufficient hepatic
for 1 wk prior to
levels for inhibition of hepatic metastasis
surgery
from colorectal cancer
* denotes number of patients In the tnal
Dose
1-4 g/day for
months
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Refs.
(30)

(31 )

(32)
(33)

These limitations of low solubility, rapid metabolism and hence low bioavailability have
limited the therapeutic success of curcumin largely to cell culture systems and elicited
only limited efficacy in various preclinical and clinical studies. In order to overcome this
problem, several advanced drug-delivery systems have been designed to provide
localized or targeted delivery of curcumin. Various drug-delivery systems - such as
nanoparticles, liposomes, microparticles and microemulsion - have been demonstrated
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to significantly enhance the preventive/therapeutic efficacy of curcumin by increasing
their bioavailability and targetability which are discussed below (34).

Curcumin Drug Delivery Systems
2.4. Curcumin Nanoparticles
The advent of nanotechnology has enabled the development of various nano-particulate
drug delivery systems that can enable the formulation of hydrophobic drugs like
curcumin (table 1.2) which earlier was a conundrum for the formulation scientists (35).
According to the National Nanotechnology Initiative (NNI), nanoparticulate (NP)-delivery
systems contain encapsulated, dispersed, adsorbed, or conjugated drugs within a
particle size range of 1-100 nm (36). These delivery systems have gained immense
popularity in the last decade due to their potential to improve the therapeutic index of the
encapsulated drugs either by protecting them from enzymatic degradation (37), by
altering their pharmacokinetics (38), by blunting their toxicity (39) or by providing
controlled release over extended periods of time (40).

Upon oral administration, colloidal particles like nano/micro-particles, are absorbed in
their intact form via Iympho-epithelial M cells of peyer's patches. These particles bind to
the apical side (towards the lumen) of M cells gets internalized, and are subsequently
shuttled to lymphocytes (41). These colloidal carriers transit slowly in the gut which
increases the local concentration gradient across the absorptive segments of the
intestine, further enhancing the absorption rate (42). NPs as drug delivery vehicles also
enables passive targeting in tumors and other inflamed tissues due to increased
vascular leakiness that results because of increased production of cytokines and
angiogenesis cascades at these sites. In majority of solid tumors, the vascular cut-off
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pore size ranges between 380-780 nm (43) whereas normal vasculature is impermeable
to particles larger than 2-4 nm (44, 45). Such a vast difference in vascular permeability
enables the passive targeting of tumor and inflamed tissues by NPs and leads to their
accumulation resulting in an enhanced permeation and retention (EPR) effect (43). As a
consequence of this passive accumulation at target sites, the concentration of the drug
at healthy tissues is correspondingly lower, thereby blunting the intensity of side effects.
However, it is noted that for patients with other patho-physiological conditions that are
associated with leaky vasculatures, drug delivery by NPs could result in distribution to
multiple sites, thereby blunting (to some extent) selectivity for tumor tissues. Such
delivery systems are particularly effective in testing and developing new chemical
entities

including

natural

compounds

like

curcumin

that

possess

sub-optimal

physicochemical and pharmacokinetic properties to be developed as new drug
candidates.

Being lipophilic curcumin partitions/encapsulates into the hydrophobic core of
amphiphilic polymers or phospholipids of NPs which not only enhance its bioavailability
but also increase its stability by protecting them from the influence of outside
environment (40). One of the most investigated method for preparing such NP
formulations is emulsion-diffusion-evaporation method which involves solubilizing the
drug and/or polymer (Poly(lactic-co-glycolic acid)) in any organic solvent like ethyl
acetate, followed by its drop wise addition into an aqueous phase that contains a
suitable stabilizer to result into an emulsion. The emulsion can then be homogenized
and diluted with a large quantity of water so that solvent diffusion can result in nanoprecipitation. This method provides uniformly sized (120-240 nm) spherical NPs of
curcumin (Figure 1.6), and since solubility of the incorporated drug plays a pivotal role in
determining encapsulation efficiency, stabilizers with lower drug solubility were found to
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be better candidates for achieving high drug encapsulation (46). In vivo studies in rats
showed that curcumin NPs increased curcumin bioavailability by 26-fold as compared to
oral curcumin suspension and by 9-fold as compared to a curcumin suspension
administered in conjunction with piperine (46). Furthermore, similar PLGA NPs, prepared
by Anand et al. (47) using F-68 as the solubilizer, were found to possess similar efficacy
as free curcumin in killing tumor cells but a higher potency in inhibiting NF-kB activation
in cell culture, compared to free curcumin. The authors of this study also claimed
superior bioavailability from curcumin NPs; this claim, however, is difficult to assess as
curcumin was administered to the mice via i. v. route where bioavailability does not come
into play.

Nonetheless, an increased half-life of the curcumin in plasma was evident

(47).

2.0
~m

Figure 1.6. Atomic force microscopy (AFM) image of curcumin-Ioaded PLGA nanoparticies
prepared by emulsion-diffusion-evaporation method (From shaikh et aI. , reproduced with
permission) (46) .
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Curcumin NPs can also be prepared using other copolymers like N-isopropylacrylamide
(NIPAAM), N-vinyl-2-pyrrolidone (VP) and poly(ethyleneglycol) monoacrylate (NIPAAM
(VP/PEG A)) (48). These NPs possess very low polydispersity with an average particle
size of 50 nm that enables them to freely permeate into different pancreatic cancer cell
lines. Although, these curcumin NPs were found to be equally efficacious as free
curcumin in cell culture but had an added advantage of their direct injectability into the
systemic circulation, thereby bypassing the oral route (48).

Another method to prepare curcumin NPs is by anionic polymerization-solventevaporation

method

(49).

This

method

involves

drop-wise

addition

of

a

butylcyanoacrylate monomer solution into a constantly stirred acidic ethanol solution
containing a suitable surfactant and sodium sulfate. At the critical micelle concentration
(CMC), surfactant molecules aggregate together to form a swollen micellar structure
containing multiple monomer units. Polymerization of monomer units occurs inside these
micelles, forming primary polymer particles that grow in size to form NPs. Curcumin or
any other chemopreventive can be added during or after the addition of monomer
solution to achieve efficient encapsulation during the growth phase. This method
provides uniform NPs (POI of 0.23-0.27) of 160-240 nm, with particle size directly related
to monomer concentration and inversely related to surfactant concentration (49).
Furthermore, it also results in the formation of a highly porous structure with a very high
surface area that can be loaded with hydrophobiC drugs like curcumin (50). These NPs
were found to provide higher drug release under in vitro conditions at acidic pH
compared to physiological pH, demonstrating their ability to efficiently deliver their cargo
inside the cells after degradation by Iysosomes, where conditions are more acidic (49).
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The other advantage of using polymeric NPs is their amenability to alterations of surface
properties. Different functional groups like thiols can be covalently or non-covalently
conjugated with the polymeric chains to increase or decrease the mean residence time
of the nanoparticles in the gastrointestinal mucosa. Grabovac

et at. prepared such PLGA

NPs modified at the surface with thiolated chitosan (40). Thiolated chitosans owing to
their -SH groups interact with mucus to form disulphide linkages conferring them with
highly muco-adhesive properties and hence an increased residence time (51).
Furthermore, due to various inter- and intra-molecular disulfide bonds between chitosan
molecules, a tight 3D structure results providing a controlled release (51). Other
mechanisms like reversible opening of tight junctions and inhibition of efflux P-gp pumps
have also been demonstrated to be associated with these thiolated chitosans (52).
Although thiolation increases the mean residence time of the coated NPs on the
mucosa, it also increases the particle size with decreased encapsulation efficiency of
drugs as compared to unmodified NPs (40). The size of curcumin NPs was found to
increase from 284-420 nm to 817-960 nm on chitosan coating with half the entrapment
efficiency limiting the drug-loading capacity of the thiolated NPs (40).

Another variant of modified NPs is formulation of multi layered polyionic/polymeric shells
encapsulating NPs containing drugs. These polyelectrolyte shells are formed as layers
over the surfaces of NPs to alter their cell uptake, to attach tumor targeting agents, to
increase stability, and/or to control their loading/release characteristics (53). These
layered NPs have been demonstrated using gelatin as the polymer and can be prepared
by a two-step desolvation method followed by formation of layered poly-ionic shells (54).
First, the gelatin NPs are prepared by precipitating gelatin from an acidified solution by
slowly adding acetone and then cross linking gelatin with glutaraldehyde.

Then, an

aqueous solution of these NPs can be coated with polyionic shells by the sequential
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addition of polyanions (polystyrene sulfonate, poly-L-glutamic acid or dextran sulphate)
and polycations (polyallylamine Hel, poly-L-Iysine, or protamine sulphate) at pH 6. Since
gelatin is positively charged at acidic pH, a polyanionic layer forms first followed by a
polycation layer. Once prepared, these NPs can be further added to curcumin solution to
adsorb curcumin at their surface via hydrophobic interactions that develop between
curcumin's phenol groups and gelatin's amino acids like proline (53).

Such

multi-layered

chemopreventives.

NPs can

also

be

modified for the

targeted

delivery of

In such nanostructures, polymeric layers with the entrapped

chemopreventives encapsulate a magnetic iron core that acts as a targeting system
(55). Efficacy of such multi-layered NPs of curcumin was demonstrated by Koppolu et
ai, (55) using poly (NIPAAM) and PLGA as polymers. In this approach, NIPAAM
undergoes free radical polymerization onto the magnetic core via covalent coupling with
a silane reagent. The resultant NPs can then be coated with PLGA using a double
emulsion solvent evaporation method, yielding NPs of 500-1000 nm size that can be
used to deliver both hydrophilic and hydrophobic chemopreventive compounds
simultaneously. The hydrophilic compounds can be loaded into the poly (NIPAAM) layer,
and the hydrophobic drugs can be loaded into outer PLGA layer (55). However,
attachment of multiple poly (NIPAAM) particles at the surface of PLGA particles as well
as encapsulation of multiple poly (NIPAAM) particles in the PLGA layer (as opposed to
the encapsulation of a single particle) raises some concerns regarding control and the
success of the formulation method.

Targeted delivery of chemopreventives can also be achieved by conjugation of NPs or
drugs with ligands like folic acid that can recognize some specific surface attributes of
target cell types. Different cancer types often over-express some specific epitopes or
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receptors (56) and bio-conjugation of chemopreventives to ligands having high
specificity for these unique surface receptors can help in achieving their targeted
delivery to any cancer type. Salmaso et al. (57) demonstrated targeted delivery of
curcumin by attaching folic acid (as a ligand) to the polymeric carrier. Presence of folic
acid enabled these NPs to undergo clathrin independent endocytosis into cells that
specifically over express folic acid receptors. This formulation involved conjugation of
PEG, covalently linked to folic acid on one end with isocyanate group of hexamethylene
which is further linked to a cyclodextrin curcumin complex on the other end.
Hexamethylene is used as a linker to decrease the steric hindrance of bulky PEG chains
with cyclodextrin curcumin complex where cyclodextrin was used to bind curcumin into
its cavity and to enhance its solubility. These conjugated complexes of curcumin were
found to be i) 3,200 times more soluble, ii) -12 times more stable, iii) 2 times more
specific, and iv) 45 times less degradable at pH 7.2 (the degradation rate constant
decreased from 321 X1 0-4 min- 1 to 7X10-4 min- 1) compared to curcumin alone (57).
However, an insufficient cell uptake led to limited beneficial effects of this bio-conjugate
and further biological investigations are required to demonstrate efficient drug release
from the conjugates into the tumor cells.

2.4.1 Solid Lipid Nanoparticles
Solid lipid nanoparticles (SLNs) are prepared by using lipids instead of polymers and
have also shown significant potential for the delivery of lipophilic compounds like
curcumin (58). SLNs were first introduced in mid 1990s as novel drug delivery systems
(59) capable of protecting the labile drugs from light/pH/heat mediated degradation,
controlled release and excellent biocompatibility/toleratability (60). These are spherical
lipid NPs with a high specific surface area that can be easily modified to i) attain a
favorable zeta potential, ii) pseudo zero-order kinetics, iii) rapid internalization by cancer
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cells and iv) impart stealth properties to lessen uptake by the reticulo-endothelial system
(RES). These properties make them highly versatile drug delivery systems for a variety
of compounds with different physicochemical and pharmacological properties (58). Their
lipophilic character enables them to cross the blood brain barrier (BBB), providing a
viable alternative vehicle for the delivery of less lipophilic drugs that cannot cross the
BBB (35). Furthermore, biological origin of lipid component of these SLNs renders them
less toxic as compared to polymeric NPs (61). This drug delivery carrier not only protects
the entrapped drug from photochemical or pH mediated degradation but also enables
drug targeting and easy large scale production (62, 63). Such characteristics make SLNs
as suitable drug delivery carriers for curcumin (table 1.2) and other chemopreventives
like resveratrol, and

~-carotene

which owing to their lipid solubility gets localized in the

bilayer membrane of lipid vesicies/NPs and results in enhanced bioavailability. Initially,
hot homogenization and warm microemulsion techniques were used for the preparation
of SLNs but later other advanced techniques like high pressure homogenization, solvent
emulsification evaporation/diffusion, high speed stirring, double emulsion method and
ultrasonication were introduced (35).

Curcumin SLNs can be formulated using dimyristoyl phophatidylcholine (DMPC) via
extrusion through a 0.2 11m filter (64). These vesicles were surface modified by Lglutamic acid, N-(3-carboxy-1-oxopropyl)-1, 5-dihexadecyl ester, and PEG to increase
their uptake by macrophages. Since, macrophages produce ROS that leads to oxidative
damage and inflammatory responses, curcumin delivery to these macrophages can
result in its maximal anti-inflammatory action. Sou et al. (64), has reported localization of
curcumin SLNs in macrophage rich sites such as bone marrow, spleen, and liver even at
6 h after the injection, demonstrating their preferential uptake by macrophages and their
considerable ROS scavenging potential equivalent to 160 to 1,050 SOD units when
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analyzed by a hypoxanthine and xanthine oxidase system (64). Although an initial
decrease in white blood cells, red blood cells and platelets was observed with these
vesicular NPs, the levels of these blood components recovered within 3 h demonstrated
absence of any acute toxic response of body towards these delivery vehicles.

The

potential of this system to deliver curcumin to different tissues was further demonstrated
by the presence of yellow fluorescence of curcumin in tissue samples of animals, as
detected by confocal microscopy (64).

One concern with this approach, however,

involves an increase in curcumin release from these vesicles at room temperature (2030°C), suggesting a possible problem with the retention of entrapped curcumin during
long storage.
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Table 1.2.
Polymeric and solid lipid nanoparticle formulations of curcumin.

Formulation

Method

PLGA NPs of curcumin for oral

Solvent
Evaporation

administration.

Diffusion

PLGA and PEG NPs of curcumin

Nano-

for parenteral administration.

precipitation

Particle

Encapsulation

Size (nm)

Efficiency (%)

120-240

77

(PDI = 0.31)
80-90

Advantages

Disadvantages

Refs.

(46)

• 26 fold increased oral bioavailability as

compared to oral curcumin suspension.
97.5

(47)

• Increased biological half-life of curcumin.
• Enhanced inhibition of TNF induced NFkB
activation as compared to free curcumin.

N
0

NIPAAM NPs of curcumin

Micellar

containing PEG monoacrylate.

Aggregation

PLGA NPs of curcumin coated

Emulsion
Solvent
Evaporation

with thiolated chitosan.

Butylcyanoacrylate NPs of
curcumin coated with poloxamer

Anionic
Polymerization
Solvent
Evaporation

-50

>90

• Increased efficacy at lower doses.
578±67

28

(pH 7.4)

160-240

layered with PLGA.

• -3.3 fold increased residence time on

gastric mucosa.

78

(PDI -0.25)

• Thiolation leads to

(40)

increased particle size.

(49)

• Highly porous structure.
• Higher drug release at acidic pH for intra-

188.

NIPAAM NPs of curcumin multi

(48)

• Direct systemic administration.

cellular delivery to Iysosomes.
Free Radical
Polymerization

500-1000

49.5

Double Emulsion
Solvent
Evaporation

Surface modified DMPC SLNs for

Extrusion
through

parenteral administration.

0.2 11M filter

• Potential to deliver both hydrophilic as well
as hydrophobic drugs simultaneously.

• Probability of encapsula-

(55)

-tion of multiple particles
inside PLGA layers

187±53

97

• Increased uptake by macrophages for
maximal anti-inflammatory activity.

• Cannot be stored for
longer periods of time.

(64)

2.5. Liposomes
Liposomes are the spherical bilayer vesicles with an aqueous interior formed by the self
association behavior of amphiphilic phospholipids with cholesterol molecules. This self
associating behavior of phospholipids originates from their tendency to shield their
hydrophobic groups from aqueous environment while interacting with the aqueous phase
with their hydrophilic groups. Depending upon their bilayer structure and size, liposomes
can be categorized as multilamellar, large unilamellar, or small unilamellar. Alternatively,
depending upon the driving force for drug release, they can be classified as conventional
liposomes, pH sensitive liposomes, cationic liposomes, immuno-liposomes and long
circulating liposomes (reviewed in ref (35)). These lipid based particulate carriers can
significantly enhance the solubility of poorly water soluble chemopreventives. Different
drugs based upon their lipophilic character can distribute either in the phospholipid
bilayer, in the interior aqueous phase, or at the bilayer water interface. The lipophilic
nature of many chemopreventives including curcumin (table 1.3), resveratrol (65, 66),
oryzanol (67), and N-acetyl cysteine (68), make them suitable candidates for liposomal
drug delivery where lipophilic core of these liposomes provide an optimum environment
for drug entrapment (69).

A liposomal system for the targeted delivery of curcumin (by coating with prostate
membrane antigen specific (PSA) antibodies) was also reported to study its partitioning
potential (70). It has been observed that DMPC based liposomes possess greater
encapsulation efficiency with a more desirable particle size of 100-150 nm as compared
to

liposomes

prepared

with

dipalmitoyl

phosphatidylcholine

(DPPC)

and

egg

phosphatidylcholine (PC). Furthermore, DMPC liposomes were found to inhibit (70-80%)
cellular proliferation of the human prostate LNCaP and C4-2B cancer cells at 5-10 11M
concentration as compared to free curcumin that required 10-fold higher doses to elicit
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similar inhibition. Both in vitro and in vivo studies have shown that liposomal curcumin is
much more effective than free curcumin at equimolar concentrations emphasizing that
liposomal

delivery

of

curcumin

can

enhance

their

uptake

and

hence

bioavailability/activity into the cells (70). A liposomal formulation of curcumin using
dimyristoyl-sn-glycero-3-phosphocholine was also tested for its effects on the modulation
of signaling pathways involving proliferation, apoptosis and angiogenesis of human
pancreatic carcinoma cells (71). When administered at 40 mg/kg (3 times/wk), this
liposomal formulation suppressed the growth of BXPC3 and MiaPaCa2 tumors in a
xenograft murine model suggesting in vivo efficacy of these liposomes (71).

Chemopreventives as liposomal formulations can also be delivered trans-cutaneously
through hair follicles (72) providing a reservoir for locally applied substances and to
enable topical administration. Jung et al. (72) investigated the penetration depth of a
novel class of amphoteric liposomes having iso-electric point at slightly acidic pH to
measure the efficiency of trans-follicular delivery of curcumin. They found that these
liposomes can penetrate -35 to 69% of the follicle length depending upon the charge on
the

liposomes,

demonstrating

their

ability

for

topical

delivery

of

lipophilic

chemopreventives for both therapeutic as well as chemopreventive purposes. However,
rapid elimination of these liposomal vesicles by active opsonization is known to limit their
overall efficacy which can be avoided by modifying the liposomal surface with polymers
such as PEG to confer stealth properties to them. Similar liposomal delivery systems are
also

reported for active

curcumin

metabolites

like tetrahydrocurcumin

(THC).

Government Pharmaceutical Organization of Thailand developed a tetrahydrocurcumin
cream formulation using phospholipid-derived THC liposomes (73). Dermatological tests
for irritation, carried out by Wattanakrai et al. (73) on human female volunteers,
demonstrated that these liposomes not only were safe but also possessed a significantly
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lower irritation potential compared to the reference material. Furthermore, a corneometer
analysis of the skin above antecubital fossae revealed a higher moisturizing effect, which
further showed that topical delivery of liposomal curcumin can be used in various skin
ailments. However, some of the major problems of this delivery system include stability,
poor batch to batch reproducibility, sterilization difficulties, and low drug loading (74).
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Table 1.3.
Liposomal formulations of curcumin for parenteral administration.
Formulation

DMPC:DMPG:Cholesterol (7:1 :8)

Method

Vortexing of SMLs

Particle

Encapsulation

Size (nm)

Efficiency (%)

N. R.

N. R.

liposomes of curcumin for parenteral

Advantages

• Increased curcumin stability in PBS.

Refs.

(75)

• Increased efficacy in inhibiting Con A
stimulated human lymphocytes and EBV

administration.

transformed B- cells.
Pegylated DMPC, Cholesterol, DMPG

Extrusion through

liposomes of curcumin for parenteral

0.22 11m filter

N. R.

N. R.

• Significant growth inhibition of Col0205

(71)

and LoVo cells in nude xenograft mice.

administration.
DMPC:DMPG (9:1) liposomes of curcumin

Extrusion through

for parenteral administration.

0.22 11m filter

DMPC liposomes coated with PSA

Sonication of SUVs

N. R.

N. R.

• Significant growth inhibition of CAL27

(76)

cells in nude xenograft mice.

tv

+:-

specific antobodies.
N.R: Not reported

100-150

N. R.

• Increased inhibition of LNCaP and C4-2B
cells at 10 fold lower doses of curcumin

(70)

2.6. Microemulsions/Microencapsulation
Microemulsions are one of the most widely-used drug delivery systems capable of
providing high drug entrapment efficiency with long term stability of hydrophobic
molecules (77). These thermodynamically stable, optically isotropic, transparent
formulations are characterized by a dynamic microstructure that results spontaneously
by mixing lipophilic and hydrophilic excipients in presence of suitable surfactants (78).
This microstructure results in high drug solubilization capacity along with free and fast
drug diffusion (79) that coupled with lipophilic nature endow them with a high potential
for delivering lipophilic compounds like curcumin not only across lipophilic cell
membranes but also through skin. Studies by Teichmann et al. (79), demonstrated that
curcumin can easily be delivered through the stratum corneum and into the complete
follicular infundibula via o/w (oil in water) micro-emulsions. These micro-emulsions can
be further formulated into hydrogel patches of chitosan or chitosan starch blends to
protect the drug from the detrimental effects of pH, light and/or oxygen mediated
degradation (80). Once these agents are micro-emulsified and entrapped into a hydrogel
like matrix, their stability increases significantly and controlled release at a desirable site
can be obtained.

Studies have shown that even after 2 months of storage at room

temperature mean hydrodynamic diameter of the oily internal phase increases slightly,
demonstrating the high stability and efficiency of such hydrogels (80). In addition, the
aqueous phase of these emulsions provides hydration to the stratum corneum and
moisturizes the skin (80). Drug release from micro-emulsified droplets can be further
augmented by using external energy sources such as ultrasonic waves. It has been
observed that on application of external energy these droplets undergo a structural
reorganization that results in the phase separation of oil droplets from the aqueous
vehicle releasing the compound (77). Similarly, a microemsulsion cream formulation of
curcumin SLNs was also described by Tiyaboonchai et al. (81). An entrapment efficiency
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of 35-70% was demonstrated for curcumin in SLNs with a diffusion mediated controlled
release pattern. In addition, the formulation was found to increase the photo stability of
curcumin where after 6 months of storage, with no significant change in the viscosity or
color of the formulation (81). Although this approach seems promising in enhancing the
delivery of potent therapeutics, its usefulness for chemopreventives has not been
established in animal and human clinical studies.

Aziz et al. (82) prepared microcapsules of curcumin with gelatin using ethanol/acetone
as coacervating agents to separate the two phases that result in precipitation of the drug
in spherical microcapsules. They prepared curcumin dispersion in the gelatin solution
followed by its addition to ethanol. A Formaldehyde solution (37% v/v) was then added
to provide rigidity to gelatin coating. It was reported that micro-encapsulation yield, drug
loading and entrapment efficiency all were significantly affected by the solubility of
curcumin in the coacervating solvents. They were higher when acetone was used to
dissolve curcumin as compared to ethanol in which curcumin tend to disperse at high
concentrations used for loading into micro-emulsions. Furthermore, the microcapsules
prepared by using acetone were found to possess better flowability and high stability
with retention of their spherical shape (82). A similar injectable microparticulate
formulation of curcumin using PLGA polymer was prepared and used in breast cancer
chemoprevention study (83). These microparticles were found to provide sustained
blood and tissue levels for around 1 month by a single subcutaneous injection with
tissue levels 10-30 fold higher in brain and lung as compared to that in plasma
suggesting their potential to sustain drug levels on subcutaneous administration (table

1.4).
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Table 1.4.
Microparticle/microemulsion formulations of curcumin.
Formulation

Method

Curcumin macrocapsules prepared

Coacervation

with gelatin.

Method

PLGA microparticles of curcumin for

Emulsion

parenteral administration.

Solvent Evaporation

Particle

Encapsulation

Size

Efficiency (%)

80-90

~m

75.5

Advantages

• Improved stability coupled with controlled

Refs.

(82)

release.
22±9

~m

75

• Sustained plasma curcumin levels for upto

(83)

a month after a single sic injection.
• Enhanced efficacy as compared to powder
curcumin.

Curcumin microemulsion (o/w)

Surfactant mediated

formulated into a hydrogel matrix for

Microemulsification

45-50 nm

N. R.

• Porous polymeric network providing

(80)

controlled release.
• Increases skin hydration.

topical application.
N
-..l

Microemulsified curcumin loaded
SLNs for topical application.

N.R.: Not reported

Microemulsification

450 nm
(PDIOA)

70

• Increased photostability.

(81)

2.7. Micelles

Micelles are nanosized colloidal particles formed due to the spontaneous self
aggregation (micellization) of amphiphilic polymers in the aqueous phase. Suitable
polymeric candidates for micellization are so designed that they have both hydrophobic
and hydrophilic segments able to self aggregate in presence of water so as to form a
hydrophilic shell and a hydrophobic core. Hydrophilic shell favorably interacts with the
surrounding aqueous medium (or with water soluble drugs) and hydrophobic core
encapsulate lipophilic drugs (84, 85). This solubilization of different compounds in
hydrophobic cores of micelles of amphiphilic copolymers is often dictated by FloryHuggins interaction parameter. This parameter is a measure of a solute's compatibility
with the micelle's core forming component and is inversely related to the drug's
solubility. A lower value of Flory-Huggins parameter signifies high compatibility between
the solute and the micelle core and hence higher solubility (86). Such drug loaded
polymeric micelles are generally thermodynamically stable and are biocompatible
formulations that can gradually release the entrapped/adsorbed drug for prolonged
period of time at a controlled rate (87, 88). Co-polymerization of PEG with hydrophobiclow molecular weight natural phospholipid compounds like diacyl lipid, fatty acid and bile
salts results in such amphiphilic polymers with self aggregation behavior (89). Moreover,
since bigger micelles and microparticles are prone to opsonization by reticulo-endothelial
system (RES) followed by their clearance through hepatic and splenic endothelial
fenestrations (90), presence of non-ionic hydrophilic PEG shell also suppresses the
opsonin adsorption and subsequent clearance by the mononuclear phagocyte system.
On the other hand presence of lipid moieties, like palmitic acid, in the hydrophobic core
results in higher curcumin encapsulation efficiency and presence of ester linkage
between PEG and palmitic acid ensures polymer hydrolysis by esterases releasing the
entrapped drug inside the cells. Such micelles showed a critical micelle concentration
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(CMC) of -0.12g/l with a particle size of -50 nm implying their thermodynamically stable
nature. However, high drug:polymer ratios required for high encapsulation efficiency is
an inherent limitation of such delivery systems (89)".

Curcumin micelles using amphiphilic block copolymer of poly(ethylene oxide)-b-poIY(Ecaprolactone) with an aim to increase its solubility and stability with controlled delivery
has also been reported (91). PCl enable the entrapment of hydrophobic drug in its core
and PEO forms the hydrophilic corona of micelles improving the biocompatibility. PEO
can also increase the circulation time of these biomaterials by hindering the uptake by
the reticulo-endothelial system (91). However, with such a copolymer system, PCl
molecular weight determines the encapsulation efficiency and particle size with
negligible effect of drug load. Photo and pH stability can also increase drastically due to
entrapment of curcumin in polymeric micelles (91). Similar behavior was also observed
by letchford et al. with PEG and PCl copolymers. They also showed that CMC was
inversely related to the PCl block length and drug solubilization in the core was a
function of degree of drug's compatibility with the core forming copolymer (86). Although
these studies showed that drug encapsulation depend upon the hydrophobicity of the
core forming copolymer, it would be more interesting to see if any correlation exist
between the hydrophobicity of the drug and the core forming copolymer block. It might
be possible that other drug polymer interactions might also contribute Significantly
towards the determination of micelle stability, CMC as well as encapsulation efficiency.
Tonnesen has shown that in presence of anionic surfactants like sodium dodecyl
sulphate, curcumin stability towards pH-mediated degradation (pH 8) increases by 1800fold due to formation of surfactant micelles and curcumin entrapment inside them (92).
However, SDS fails to protect curcumin at very high pH (pH 13) and at such a high pH
cationic surfactant like cetyl trimethyl ammonium bromide and dodecyl trimethyl
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ammonium bromide afford much higher protection as compared to SDS (93). It has been
postulated that at slightly basic conditions (pH 8), negatively- charged head groups of
surfactant anions repel -OH- ions and hence protects curcumin molecules to come in
contact with these ions. However, at very high pH (pH 13), curcumin exists as a triplycharged anion (cur3+) which can be effectively entrapped in cationic micelles.
Furthermore, due to this high negative charge, it also dissociates from SDS anions and
hence is less protected from the deleterious effects of pH (93). However, considering
high decomposition rate at pH 7.4 slow release kinetics of curcumin from these
nanomicelles limit their ability to deliver therapeutically relevant amounts to the targeted
tissues.

Similar micellization behavior of milk casein has also been reported to be effective for
improving curcumin's oral administration. Milk has always been used as a preferred
delivery system for the curcumin delivery in the traditional medicine for its antiinflammatory properties. Recent developments have shown that milk casein exist as
almost spherical micelles with an average size distribution of <200 nm and can complex
hydrophobic drugs like curcumin via hydrophobic interactions. Caseins exist as micellar
nanostructures held together by hydrophobic interactions and by calcium phosphate
bound at phosphorylated serine residues (94). These casein nanomicelles efficiently
bind curcumin molecules in their hydrophobic interior via interactions with their
tryptophan and tyrosine residues. However, cell culture studies did not show much
difference in the IC50 concentration of casein curcumin complex with that of free
curcumin (94). But considering the fact that in traditional medicine, turmeric is often
given in hot milk, such a delivery system might significantly enhance the bioavailability of
such a compound. Recently, inclusion and non-inclusion complexes of drugs with
hydroxyl propyl y cyclodextrin were found to self associate to form nanoscale aggregates
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that can solubilize lipophilic drugs like curcumin in a micelle like fashion. These nanomicelles localize to the subcutis, in the hair sheath and in the base of the hair follicles, on
tropical application. This delivery system could provide specific delivery of curcumin to
the epidermal cells that form the internal root sheath or to the hair follicles for dermal
ailments (95).

It is clear that micellization can effectively enhance its solubility as well as stability.
However, the main concern with this delivery system is the effect of dilution by the body
fluids on parenteral administration. At the reported CMCs for these micelles, it is highly
likely that these amphipathic polymer molecules will rapidly disassemble due to dilution
on i. v. administration, rapidly releasing the whole drug load. Considering curcumin's high
rate of metabolism, the injected drug might get eliminated out of the body within hours.
To overcome this limitation, it is required that copolymers with very low CMC should be
designed that can slowly release the encapsulated drug over longer periods of time.

Although research on most of these delivery systems has demonstrated the potential for
increasing bioavailability, two important aspects still need attention: 1) the occurrence of
rapid drug metabolism (e.g. for curcumin), which may be mitigated by the application of
combination therapies such as with piperine-like enzyme inhibitors; and 2) the need for
frequent parenteral dosing, in order to maintain effective therapeutic concentrations in
the blood.

Background, Significance and Hypothesis of the Project

Considering the above described potential limitations of curcumin, it appears that this
chemopreventive drug needs a "24/7" delivery system like polymeric implants that can
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continuously release the drug into the systemic circulation without the need for frequent
administration.

Polymeric

implantable

drug

delivery

systems

are

prepared

by

homogenous entrapment of drugs in a polymeric matrix and can be effectively used to
achieve sustained localized delivery with complete bioavailability into systemic
circulation (96). These delivery systems slowly release encapsulated drug directly at the
site of implantation to act either locally or to get absorbed into systemic circulation for
distribution to other organs. Since these implants are mostly used for local delivery of
anticancer drugs, their associated systemic toxicity is significantly minimized with
maximizing the drug present at its site of action (97). Furthermore, due to their slow
release kinetics, implants can provide drug release ranging from months to years which
improves patient compliance (98). These polymeric implants has been found to be
effective for many chemotherapeutic drugs and several of such implants are approved
by FDA for cancer chemotherapy (table 1.5) (99).

Table 1.5.

FDA-approved implants for cancer chemotherapy (99).
Device

Drug

Polymer

Disease

Decapeptyl

(D-Trp6)LH-RH

PLGA

Prostate Cancer

Lupron Depot

Leuprolide

PLGA

Prostate Cancer

Zoladex

(D-Ser(Bu)6AzG ly1 O-GnRH

PLGA

Prostate Cancer

Gliadel

Carmustine

PCPP-SA

Malignant Glioma

There are 2 type of implantable drug delivery systems, reservoir type and matrix type. In
reservoir type implants, drug core is coated by a semi permeable polymeric membrane
which controls the rate of drug release and is dependent upon the rate of water influx
into the system (Figure 2.6) (99). But these reservoir type implants are often
discouraged due to their probability of dose dumping (98). Matrix type implants, on the
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other hand, are prepared by homogenously dispersing the drug into the polymeric matrix
from where drug gets release into the surrounding medium is mediated by diffusion.
These implants are devoid of any dose dumping phenomenon and provide desirable
biphasic drug release kinetics (Figure 1.7) (99). This biphasic release consists of a burst
release followed by a slow controlled release . Initial burst release delivers the drug for
distribution to a large volume , to rapidly reach the therapeutic concentration and a slow,
controlled release maintains the therapeutic concentration for a prolonged period of time
(Figure 1.8, type (C) release) (100) desirable for natural chemopreventive compounds
like curcumin .
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Figure 1.8. Illustrates drug release from 3 theoretical implants. Zero order release (A) from
implants may take longer time to reach the therapeutic concentration. A huge burst release (B)
from implants may deliver large amounts of drug initially, but may not maintain it at therapeutic
levels after some time. A Biphasic release from implants (C) provides an early burst release to
rapidly achieve the therapeutic concentrations with a controlled release to maintain therapeutic
concentrations (100) .

Therefore, we hypothesized that direct systemic administration of curcumin by matrix
type polymeric implants can enhance its chemopreventive efficacy by (i) bypassing
the oral route (ii) eliminating the first pass metabolism and/or by reducing the
effective doses required as compared to traditional oral route. To test this hypothesis,
we propose following specific aims:

Specific Aim 1. To develop and optimize polymeric implants. Polymeric implants will
be prepared by extrusion method using water-insoluble (polycaprolactone) and watersoluble polymers (e.g. , F-68, cyclodextrin or poly(ethyleneglycol)) as additives. The drug
release kinetics from these implants will be optimized with respect to their drug load,
surface area, polymer molecular weight, % of additives to achieve a controlled drug
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release. These optimization studies will be carried out under in vitro conditions by
simulating in vivo extracellular fluid conditions (chapter II).

Specific Aim 2. To study the tissue distribution of curcumin administered by the
polymeric implants as well as by the oral route. An HPLC method will be developed
and validated for analysis of curcumin in various tissues. This HPLC method will then be
used to study curcumin distribution in tissue like plasma, brain and liver with or without
the use of tandem mass spectroscopic techniques (chapter III).

Specific Aim 3. To analyze the safety of implants by measuring various
inflammatory, proliferative and immune responses. The polymeric implants will be
analyzed for their safety in animals by measuring the immunological responses of
neutrophils, lymphocytes and macrophages towards implants. Effects on various liver
and kidney functions along with changes in various hematological parameters will be
evaluated to determine any acute/chronic toxicity associated either with implants or with
continuous systemic administration of high doses of curcumin. Pathophysiological
studies will also be carried out by histology using H & E staining to determine the
intensity of inflammatory reactions at the site of implantation and at adjacent sites
(chapter IV).

Specific Aim 4. To determine the chemopreventive/chemotherapeutic efficacy of
curcumin delivered via polymeric implants as compared to administered by oral
route. Pharmacodynamics of curcumin delivered by these implants as well as the by the
traditional

oral

route

will

be

studied

using

estrogen-mediated

rat

mammary

tumorigenesis model. Relative efficacy of curcumin treatment by both routes will be
determined by analyzing modulation of the various tumor indices (tumor latency, tumor
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incidence, tumor multiplicity, and tumor volume) as well as selected molecular targets
(chapter V).

Significance of the Project
Data gathered from this research project will provide a drug delivery system that can (i)
enhance bioavailability and lower the effective dose of chemopreventive agents
compared with dietary route, (ii) allow testing of other agents that cannot be tested for
their efficacy under in vivo conditions due to their limited quantities; and iii) deliver
chemopreventive/chemotherapeutic agents at the target site at controlled doses thus
minimizing systemic toxicity. The outcomes will also enable to develop effective
strategies for metronomic chemotherapy where low, sustained plasma concentrations
(much below their therapeutic concentration) of active compounds are maintained for
extended periods of time.
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CHAPTER II
DEVELOPMENT AND IN VITRO-IN VIVO EVALUATION OF POLYMERIC
IMPLANTS FOR CONTINUOUS SYSTEMIC DELIVERY OF CURCUMIN

Rationale
Drug release from implants is a dynamic process that largely depends upon the
surrounding

environment

and

polymer characteristics

(100).

Extracellular fluid

composition and volume can drastically alter the rate and extent of drug release (96).
Basal rate of drug release from these implants is dependent upon the rate of diffusion of
extracellular fluid (ECF)/release media inside the matrix, its tendency to dissolve the
drug and efflux of fluid into the surrounding media (100). Other factors like implant
surface area, drug load; formulation additives may also contribute significantly to alter
the drug release (101, 102) and hence need to be evaluated and optimized for desired
release kinetics. Furthermore, depending upon the polymer degradation characteristics,
implants can degrade only at the surface (surface erosion type) or degrade slowly in the
bulk of the implant (bulk erosion type) to releaser the drug (103). This degradation and
release behavior of implants is determined by the hydrolysis rate of polymeric chains
and hence polymer selection is the most critical factor in the development of clinically
useful implants (103). POIY(E-caprolactone) (PCl) is an FDA-approved polymer that
undergoes bulk erosion with very slow degradation rates and may take months to years
to get hydrolyzed (104). Its low melting point (58-60°C) makes it a suitable candidate to
be used for natural chemopreventives which are often thermolabile (105). The focus of
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this specific aim, therefore, will be to investigate the influence of the indicated variables
on curcumin release from pel implants under simulated in vitro conditions. Results from
these studies will provide useful insights regarding the changes in drug release kinetics
with changes in drug load, surface area, presence of water-soluble additives and
polymer degradation rate. The outcomes will enable us to identify rate determining
variables and to alter them to achieve a desirable rate of drug release.
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Materials and Methods
Materials
Oichloromethane, poly (E-caprolactone) 15,000 and 65,000 molecular weight (PCl-15
and PCl-65), 2-hydroxypropyl l3-cyclodextrin and phosphate-buffered-saline (PBS)
tablets were purchased from Sigma (Sigma-Aldrich, Inc., MO, USA). F-68 was a
generous gift from BASF Corporation (Campus Dr., NJ, USA). PEG-8,000 was
purchased from Fisher Scientific (New Jersey, USA), ethanol from Pharmco-AAPER
(KY, USA) and bovine calf serum (BCS) from Hyclone (Utah, USA). Silastic tubing (3.4
mm external diameter) was purchased from Allied Biomedical (Ventura, CA, USA) and
curcumin (>98% purity) was purchased from Across Organics (New Jersey, USA). All
the materials were used as received without any further analysis.

Methods
Preparation of Curcumin Implants
Curcumin implants (2, 5, 10 or 20% w/w) were prepared by melt-extrusion technique.
Briefly, the polymer (PCl) and curcumin were dissolved in dichloromethane (OCM) and
ethanol, respectively and mixed together in the presence or absence of a water-soluble
polymer to prepare a homogenous solution of drug and polymer. After evaporation of the
solvents at 70°C on a water bath, the semi-solid residue was dried overnight under
vacuum at 65 °C to ensure complete removal of solvents. The dried drug-polymer
mixure was filled in 3-ml syringes, heated at 65°C and molten drug-polymer mixture was
extruded through silastic tubing mold attached to the syringe. After few min, the
cylindrical implants (3.4 mm external diameter) were removed from the tubing and
excised into desired sizes (0.5, 1.0, 1.5 and 2.0 cm) and stored at -20°C in amber color
vials under argon until use.
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Curcumin Stability studies
Curcumin (300 I1g) was added to 10 ml PBS, PBS supplemented with 10% (v/v) BCS or
to 0.7% albumin solution in PBS taken in amber colored vials. The vials were then
incubated at 37±0.5 °C in a shaker water bath (Julabo SW23, Germany) shaking at 150
rpm. At different time intervals, 300 III of solution was aliquoted and analyzed by UV
spectrophotometry (Spectramax M2, Molecular Devices, USA) to determine the
degradation rate of curcumin in different medias.

Differential Scanning Calorimetry (DSC) Studies
DSC studies were carried out by heating 6-9 mg of each sample from 28°C to 200°C at
a rate of 10 °C/min (DSC Q20 from TA instruments) in hermetically sealed aluminium
pans constantly purged with nitrogen at a flow rate of 50 ml/min. The data was analyzed
using Universal Analysis 2000, version 4.5A software.

Powder X-ray Diffraction (PXRD) Studies
PXRD studies were carried out by using Bruker AXS D8 Diffractometer and data was
analyzed using XRD commander version 2.6.1 software. The samples were placed onto
polymethylmethacrylate (PMMA) sample holder, leveled manually with a clean glass
slide and scanned over an angular range of 5° to 55° 2-theta scale with a step time of
0.2 sec.

Analysis of Residual Solvents (DCM) by Gas Chromatography
Since a class II solvent, dichloromethane, was used during the implant formulation;
Implants were analyzed for residual DCM content by gas chromatography. Sham
Implants (1 cm) were dissolved in 1ml tetrahydrofuran (THF) followed by addition of 3 ml
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methanol to precipitate the polymer. Polymer was separated using centrifugation at
10,000 g for 10 min and 1111 of supernatant was injected into the column (DB5MS, 20 m
X 0.18 mm) with a split ratio of 70: 1. The molecular ion peaks were measured using
selective ion monitoring and using THF (molecular ion peak at 31) as the internal
standard. The amount of DCM was calculated by using a calibration curve prepared in
the similar manner.

In Vitro Drug Release
Release of curcumin from implants (equivalent to 2, 5, 10 or 20 mg/cm in 2, 5, 10 or 20%
w/w) was determined under simulated in vitro conditions. Briefly, implants were agitated
in 5 ml PBS (pH 7.4) supplemented with 10% (v/v) BCS at 37±0.5 °C in a reciprocating
shaker water bath (Julabo SW 23, Seelbach, Germany) (150 rpm) and the release
medium was changed after every 24 h. PBS was supplemented with BCS (10% v/v) to
mimic extracellular fluid composition and to simulate the in vivo situation. Albumin
present in the BCS binds curcumin via vander Waals forces of interaction and provides
perfect sink conditions for release of curcumin (106). Curcumin concentration was
measured spectrophotometrically at 430 nm against a standard curve following the
addition of ethanol (10%, final concentration) to ensure complete dissolution of
curcumin.

Scanning Electron Microscopy (SEM)
Surface morphology of implants was studied by SEM using Jeol JSM-5310 (Jeol Ltd,
Tokyo, Japan). Sections of the implants before and after the in vitro/in vivo release were
cut and mounted on a copper base with carbon glue. The sections were sputter coated
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with gold using Spi-Module sputter coater (SPI Supplies, West Chester, PA) and
analyzed at 25 kV.

Content Uniformity of Implants
Drug contents in implants (n=3) were analyzed to determine the homogeneity of drug
distribution and to verify the amount of drug incorporated in each implant..Gne-~plant..s
(equivalent to 10 or 20 mg drug/cm implant for 10 or 20% drug load) were weighed and
dissolved in 5 ml DCM. Once the implants were dissolved, 5 ml ethanol was added to
completely dissolve the drug. The solution was then diluted suitably with ethanol and
drug concentration was measured by UV spectrophotometer at 430 nm (Spectramax
M2, Molecular Devices, USA).

Residual drug in the implants recovered from animals was also measured similarly and
the average rate of release was calculated as follows:
Average Daily Release

=

Initial amount - Residual amount
Time (days)

Stability Studies
Implants (1 cm) with 20% drug load were prepared using the standardized procedure
and individually stored in amber colored vials. The vials were sealed by parafilm and
stored in dark at 4, 25 and 40 DC for a period of 1, 3, 6 and 12 months. After specific time
intervals, implants were removed and analyzed for curcumin content as described in
content uniformity section. The implants were also studied for changes in their release
kinetics after storage at above temperatures for 4 months.
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Results and Discussion

Stability of Curcumin in Different Media
Curcumin is highly unstable at physiological pH (pH 7.4) and instability increases further
with pH (107). However, it is known that presence of plasma proteins increases
curcumin's stability and increases its half-life from -30 min to -8 h (106, 107). Therefore,
we determined the stability of curcumin in presence and absence of albumin as well as
in simulated extracellular fluid (ECF) conditions using PBS supplemented with 10% (v/v)
BCS (Figure 2.1). It was found that curcumin exhibits first-order degradation kinetics
where rate of curcumin degradation was proportional to its concentration in the solution.
Curcumin was highly unstable in PBS and -90% drug degraded within 2 h (107). The
presence of serum and albumin were found to increase the stability of curcumin
substantially. The half-life increased from few min to 39 h with BCS and to 131 h with
albumin . These results suggest that albumin and other components bind curcumin and
hence stabilize it towards pH-mediated degradation (106).
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Figure 2.1 . Degradation behavior of curcumin in phosphate-buffered saline (PBS), PBS
supplemented with 10% bovine calf serum (BCS) and 0.7% albumin solution (n=3, SD<5). The
ordinate axis represents logarithm of drug concentration after specific time intervals.
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Differential Scanning Calorimetry (DSC) Studies
To check the thermal stability of curcumin and polymer, both the components alone as
well as in combination were analyzed by DSC ~ Curcumin and polymer both were found
to be stable by differential scanning calorimetry (Figure 2.2) . Melting temperature (Tm) of
PCl-65 was found to be 60-61 DC (104) and that of curcumin at 177 DC (108). However,
drug-polymer blend showed presence of only one melting endotherm at 58 DC
corresponding to PCl polymer and no melting endotherm corresponding to curcumin
was observed at 10% drug load (10 mg/cm). The absence of curcumin melting
endotherm by DSC in the implants revealed that the drug was dispersed at a molecular
level in the polymer matrix at 10% w/w composition and was stabilized in its amorphous
form by the polymer (109) . However, slight crystallization was observed at 20% w/w drug
load with a broad melting endotherm suggestive of slight curcumin crystallization at
higher drug loads.
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Figure 2.2 . DSC thermograms of PCl-55, curcumin and their implants. These studies were
carried out by heating each sample (5-9 mg) from 28 DC to 200 °C at a rate of 10 °C under
constant nitrogen purge.
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Powder X-ray Diffraction (PXRD) Studies
PXRD studies confirmed the semi-crystalline nature of PCl with presence of 2
characteristic peaks at 23° and 25.5° (Figure 2.3). Curcumin on the other hand revealed
a crystalline structure with presence of number of characteristic peaks at 17.5, 18.5,
21.5, 25, 26 and 28° (110). Implants containing 10% (w/w) curcumin in PCl, however;
showed a halo pattern with presence of only 2 peaks characteristic for PCl. These
results further confirmed the amorphization of curcumin at 10% (w/w) drug loading in
implants.
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Figure 2.3. Powder X-ray diffractographs of pel, curcumin and implants containing 10% (w/w)
curcumin . The samples were placed onto polymethylmethacrylate (PMMA) sample holder,
leveled manually with a clean glass slide and scanned over an angular range of 5° to 55° 2-theta
scale with a step time of 0.2 sec.
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Drug Content Analysis
To ensure the homogenous distribution and batch to batch reproducibility of curcumin in
the polymer matrix, 1-cm implants (10 mg drug/cm implant) were dissolved in
DCM:ethanol (1:1), suitably diluted and were measured for curcumin. Analysis of drug
content in implants showed that the implants were uniform with homogenous dispersion
of drug. Almost 95% ± 1.2% drug was recovered from PCl implants prepared in the
same batch or different batches, with negligible variability in drug loading between the
implants prepared at different times. This showed that curcumin implants prepared under
these conditions were reproducible with respect to drug content and drug distribution.

In Vitro Drug Release: Effect of Polymer Molecular Weight
Since molecular weight of polymers is one of the determining factors for rate of influx
and efflux of extracellular fluid through the polymeric matrix (111), different implants
were prepared by blE:mding PCl of 15,000 (PCl-15) and 65,000 (PCl-65) molecular
weight in different proportions with 10% drug load (10 mg/cm). The implants were then
analyzed for their daily drug release for up to -140 days (Figure 2.4). Data showed that
initially -17% drug was released from PCl-15 implants in one week as compared to
around 13% from PCl-65 implants and decreased slightly with increasing concentration
of PCl-65. Daily drug release was slightly higher from PCl-15 implants during first week
as compared to PCl-65 after which it was similar from both the implants up to 60 days.
However, after -60 days drug release was higher from PCl-65 implants as compared to
PCl-15. Daily releas'9 from PCl-65 implants was -3 times higher (30-35 Ilg/day) as
compared to PCl-15 implants (10-12 Ilg/day) after 100 days. It appears that the pore
size of the polymeric matrix of both PCl-15 and PCl-65 is greater than the molecular
size of the curcumin molecules and hence is not the limiting factor for the drug diffusion
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during initial period. However, with time when the path length of solvent diffusion
increases PCl-65 offers least resistance to the drug release and hence the drop in daily
drug release is minimal with PCl-65 implants (112).

This study also showed that drug release from these polymeric implants follow biphasic
release kinetics. A burst release was observed initially which declined rapidly during the
first 25 days followed by a much slower decline for next 100 days. Two hundred to 250
I1g curcumin was found to be released on day 1 which then declined with time and
dropped to <100 I1g/day after 20 days. This burst release could be due to release of
surface-bound drug, followed by a more controlled release from the inner layers of
implant's polymer matrix. Such a burst effect can be useful in cases where rapid
achievement of plasma concentration of therapeutic agents is desired which can then be
maintained with slow controlled release of drugs (100). However, in cases where such a
burst release is undesirable, these implants can be incubated in ethanol for 1-2 h to get
rid of most of the surface bound drug. Furthermore, the decline in drug release during
the diffusion from the inner layers of polymeric matrix could be attributed to either
reduction in drug's permeability due to increased crystallinity of polymer and/or due to a
decrease in concentration gradient of drug in outer layers of polymer matrix (111). It is
known that due to semi-crystalline nature of PCl, its crystallinity increases with time in
presence of aqueous release media which might result in increased resistance for
diffusion of aqueous fluids and hence decreasing the drug release with time (102).
Moreover, a decrease in concentration gradient of drug in outer polymer layers result in
longer path length for diffusion of aqueous fluid into deeper layers which also result in a
decrease in drug release (102). However, when cumulative release data (Figure 2.4
inset) from these implants was analyzed by zero order, first order, Higuchi and Hixson
Crowell models for drug-release kinetics (113), it was found that drug release from PCl
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implants followed diffusion-mediated Higuchi kinetics (r2 > 0.98). It shows that pel
implants are able to release drug at a controlled rate over an extended period of time
and the drop in drug release was indeed partly due to longer path length of diffusion
(113).

The implants were also analyzed by SEM before and after the in vitro release. The
freshly-prepared implants were found to be smooth with homogenous dispersion of drug
without any visible evidence of discontinuities. No significant difference was observed in
the polymeric matrix 140 days after the in vitro release which showed that the polymeric
matrix was stable in the release medium for at least this period of time. However, small
amount of drug crystallization was observed in these implants which might be due to
slow crystallization of amorphous drug in the polymer matrix that can occur when it
comes in contact with the aqueous release media (Figure 2.Sa-c).
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Figure 2.5. Scanning electron microscopy pictures (1 ,000 times magnification) of (a) sham
implant (b) implant with 10% drug load, (c) implant with 10% drug load after 140 days of release
under in vitro conditions, (d) Implants with 20% drug load , (e) implants with 30% drug load and (f)
Implants with 20% drug load showing traces of crystallization (2,000 times magnification).

Effect of Drug Loading
These implants were also analyzed for the effect of drug loading on daily drug release. It
has been found that due to channeling effect, increasing drug loads lead to higher drug
release (114). Therefore, implants with 2%, 5%, 10%, 20%, 30%, 40% and 50% drug
load (2, 5, 10, 20, 30 , 40 and 50 mg per cm implant, respectively) were prepared and
analyzed for daily drug release (Figures 2.6 and 2.7). It was found that drug release was
proportional to drug concentration for only up to 10% drug load and no further increase
in the release was observed with higher drug loads. Daily drug release was -2-3 times
higher from 5% implants as compared to 2% implants and similarly was 1.7-1.9 times
higher from 10% drug load implants as compared to 5% drug load at all-time points. It
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appears that only up to 10% drug load, the channeling effect increases, enhancing the
porosity of matrix for diffusion of release media. But, at higher drug loads, solubility of
curcurriin in the polymeric matrix becomes a limiting factor. Furthermore, due to lipophilic
nature of curcumin, increasing drug concentration lead to an increase in lipophilicity of
the curcumin-polymer matrix which could also be a contributing factor leading to
retardation of influx of release medium (112). SEM analysis of these implants showed
that at drug loads > 10%, degree of discontinuities and extent of drug crystallization in
the polymeric matrix also increased proportionately (Figure 2.5d, e and f) which could
also be a limiting factor.
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Effect of Surface Area
Since the drug release from implants was found to follow diffusion mediated 'Higuchi
kinetics, it was expected that an increase in surface area should proportionately increase
the drug release. Therefore, to study the effect of surface area, implants of different
sizes were prepared: 0.5 cm with a surface area of 0.69 cm 2 (10 mg drug), 1 cm with a
surface area of 1.21 cm 2 (20 mg drug) and 2 cm with a surface area of 2.24 cm 2 (40 mg
drug); and analyzed for daily drug release (Figure 2.8) . As expected, a proportionate
increase in drug release was observed with increasing surface area. Daily drug release
from 1 cm implants was - 1.6 to 1.8 times higher as compared to 0.5 cm implants after 1
week. Similarly, daily drug release from 2 cm implants was 1.3 to 1.5 times higher as
compared to 1 cm implants. Since drug release from these implants was diffusion
mediated, according to Fick's law of diffusion as the size of the implants increases, the
effective surface area for diffusion of extracellular fluid increases, which in turn ,
increases the amount of drug efflux from the polymeric matrix (115). Therefore, in order
to have maximum drug release, 2-cm implants were selected for further studies.
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Figure 2.8. Effect of surface Area (implant size) on daily drug release . Data presented denote
average of three replicates . SO , generally 5-10% has been excluded for clarity.

Effect of Formulation Additives
Addition of certain excipients in the polymeric matrix influences drug release
significantly. They may increase or decrease the drug release rates by changing the
matrix lipophilicity, matrix porosity, microclimate pH and or polymer drug interactions
(101 , 116). Excipients, especially, hydrophilic polymers compatible with the polymeric
matrix are helpful in providing aqueous channels to facilitate the diffusion mediated drug
release. Due to their water solubility, such hydrophilic excipients preferentially dissolve in
the ECF and form a porous matrix enhancing the drug release (117). This effect is more
profound in case of less permeable polymeric matrices, especially where drug release is
dictated by diffusion through the polymer. Furthermore, a reduction in implant's rigidity
and viscosity due to a relative decrease in matrix forming polymer content (due to
addition of water soluble polymers) might also be a contributing factor towards
enhancement of drug release.
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Therefore, we studied the effect of several water-soluble polymeric additives for their
influence on drug release. Implants were prepared using PCl-65, 20% drug load and
10% of either F-68, PEG-8,000 or 2-hydroxypropyl

~-cyclodextrin

(HPCD) and the drug

release was compared with the control implants prepared without any such additives
(Figure 2.9). It was observed that the presence of 10% F-68 or PEG decreased the drug
release to some extent as compared to control implants. Implants prepared without any
additive or with HPCD showed 12% drug release over a period of 31 days as compared
to 9.5% drug release from implants prepared with F-68 or 11 % with PEG. However,
when PEG concentration was increased to 35% (w/w) , a much higher burst release was
observed with higher release for around first 20 days as compared to implants with 10%
F-68 (Figure 2.10). Furthermore, since higher concentrations of PEG are expected to
decrease the half-life of degradation of polymeric matrix, all implants used for in vivo
studies were prepared with 35% (w/w) PEG as a formulation additive.
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Figure 2.10. Effect of 35% (w/w) PEG of 8000 molecular weight (PEG) on daily drug release as
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Effect of Porogens/salts
It is known that certain salts like ammonium bicarbonate ((NH 4h C03) helps in forming a
porous matrix by releasing CO 2 on coming in contact with water (118). Therefore, we
prepared P-65 implants with 20% drug load, 10% F-68 and 20% of either (NH 4 hC0 3 ,
citric acid or NaCI. However, it was observed that (NH 4hC0 3 released CO 2 even while
heating during initial stages of implant preparation which was undesirable. On the other
hand, implants with NaCI and citric acid did not show any significant increase in drug
release (Figure 2.11). Furthermore, increasing the NaCI concentration from 20 to 50%
also did not enhance the drug release (Figure 2.12). Therefore, salts were excluded from
the formulation.
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Figure 2.11 . Daily drug release from implants prepared with NaGI or citric acid (20% (w/w))
compared with control implants with no salts. Data presented denote average of three replicates.

-C)
:::1.

450

-+- Control
___ 20% NaCI

375

- . - 30% NaCI
-a- 40% NaCI
__ 50% NaCI

o +---~----~----~----~--~----~----~--~
4
12
16
20
o
8
24
28
32
Days
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Effect of Storage on Drug Release and on Stability of Entrapped Drug
Since we found that curcumin was dispersed in the polymeric matrix in amorphous form
it was expected that with time amorphous curcumin might tend to revert back to its more
stable crystalline form during storage. Since, amorphization of curcumin was one of the
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reasons that increased its solubility in the release medium, we wanted to study if storage
of implants affects the daily drug release. Therefore, 1-cm implants with 20% w/w drug
load (20 mg drug/cm implant) were prepared and stored in dark at 4, 25 and 40

ec, to

determine the effect of storage and of different temperature conditions on daily drug
release (Figure 2.13). As evident from the figure, daily drug release profile was unaltered
with almost similar amounts of drug being released from all the implants stored at
different temperatures for 4 months, suggestive of stability of these implants with respect
to drug release for a period of at least 4 months.
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Figure 2.13 . Implants were stored for 4 months at different temperatures (4, 25 and 40 °C) to
determine the effect of storage and temperature on daily drug release . Data presented denote
average of three replicates . SO , generally 5-10% has been excluded for clarity.

Furthermore, the effect of storage and temperature was also studied on entrapped
curcumin content by measuring the amount of curcumin in implants. As is shown in table
2.1, almost similar levels were observed in all implants stored at 4, 25 and 40

ec for 1, 3,

6 and 12 months suggestive of curcumin's stability in the polymeric matrix for at least 1
year.
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Table 2.1.

Effect of storage on curcumin content in implants stored at different temperatures for a
period of 1 year.

Curcumin Content

4°C
Mean
(mg)

SO

0

17.88

0.2

1

16.62

0.3

17.7

3

18.34

0.2

6

17.5

12

17.3

Time
(Months)

25 °C
Mean
(mg)
SO

40 °C
Mean
(mg)

SO

0.4

16.9

0.4

18.44

0.4

18.94

0.2

0.1

16.68

0.5

16.14

0.3

0.1

17.23

0.2

17.71

0.1
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Conclusions
In this study we developed and optimized polymeric implants of curcumin with an aim to
bypass the oral route and to enhance its efficacy by continuously delivering curcumin at
a controlled rate, directly into the systemic circulation. Curcumin due to its lipophilic
nature was found to be miscible with the polymer and showed a diffusion-mediated
biphasic release pattern in accordance with Higuchi kinetics. Drug release was found to
increase with increasing surface area, drug loads for up to 10% (w/w) and with PEG-8k
at 35% w/w composition. Furthermore, different porogens and water soluble excipients
like F-68, HPCD and PEG-8K at 10% (w/w) load were found to be ineffective. These in
vitro studies showed that polymeric implants could be a viable alternative for the delivery

of potent chemopreventives like curcumin and afford a continuous ("24/7")-delivery
system that needs to be further optimized under in vivo conditions.
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CHAPTER III
TISSUE DISTRIBUTION OF CURCUMIN FROM POLYMERIC IMPLANTS AS
COMPARED TO ORAL ADMINISTRATION

Rationale
In vivo drug release often does not correspond to in vitro drug release due to the

presence of endogenous enzymes, lipids and other constituents in extracellular fluid
(ECF) (100). Furthermore, presence of perfect sink conditions in tissue environment
(which are often difficult to achieve under in vitro conditions) also increases the drug
release. This dynamic nature of tissue environment exerts a significant influence on
efficacy of such polymeric implants (100). Therefore, focus of this section was to
investigate in vivo release from polymeric implants after subcutaneous (sic) implantation.
Drug distribution in tissues would provide evidence regarding the release and distribution
of drug in various tissues through systemic circulation as well as at local site of
implantation. Therefore, drug concentration was measured in highly perfused tissues
including plasma, liver and brain to determine drug concentration achievable through
systemic distribution. Furthermore, modulation of hepatic xenobiotic metabolizing
enzymes was also studied as a preliminary measure of chemopreventive efficacy of
curcumin (8, 13) delivered via implants.
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Materials and Methods
Materials
Medical grade poly (E-caprolactone) of 121,000 molecular weight (PCl) was purchased
from

SurModics

Pharmaceuticals

(Birmingham,

Al).

Oichloromethane

(OCM),

acetonitrile, anhydrous citric acid and phosphate-buttered-saline (PBS) were purchased
from Sigma-Aldrich (St. louis, MO), polyethylene glycol of 8,000 molecular weight (PEG)
from Fisher Scientific (Fair lawn, New Jersey), ethanol from Pharmco-AAPER
(louisville, KY). Bovine calf serum (BCS) was purchased from Hyclone (logan, UT) and
silastic tubing (3.4 mm internal diameter) from Allied Biomedical (Ventura, CA).
Curcumin (C-3 complex) extracted under GMP (good manufacturing practices) was a
generous gift from Sabinsa Corporation (East Windsor, NJ). All the materials were used
as received without any further analysis.

Methods
Preparation of Curcumin Implants
Curcumin implants were prepared by following the procedure described in chapter 2.
Briefly, curcumin (20% w/w) was dissolved in ethanol and polymers (PCl and PEG in
65:35 ratio) were dissolved in OCM. Both solutions were then mixed together to prepare
a homogenous solution of drug and polymers. The solvents were evaporated on a water
bath maintained at 65°C, followed by overnight drying under vacuum at 65°C to remove
residual solvents to prepare an amorphous molecular dispersion of drug in polymer. The
dried molten polymer was then extruded through silastic tubing mold attached to a
syringe. After few min, the cylindrical implants (external diameter 3.4 mm) were removed
from the tubing and excised into desired lengths (2 cm, 200 mg containing 40 mg drug)
and stored at -20°C under argon until used.
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In Vivo Studies
In vivo cumulative release was studied in female ACI (Augustus Copenhagen Irish) rats

following an approved protocol from the Institutional Animal Care and Use Committee
(IACUC). Animals were provided with purified diet; AIN-93M and purified water ad libitum
until termination of the study. Two 2-cm implants containing 20% (w/w) curcumin (20
mg/cm) were subcutaneously grafted at the back of the 7-8 week-old female rats as
described previously (119). Animals were euthanized at different time intervals by
asphyxiation and blood, liver, brain, local tissues and implants were collected. Implants
were dried overnight under vacuum, weighed and stored at -80 DC until analysis of the
residual curcumin content.

Residual Drug Determination/Cumulative Drug Release
Initial and residual curcumin content in implants (n=3) was analyzed to determine the
cumulative drug release. Implants recovered from animals were dried over-night under
vacuum and dissolved in 5 ml DCM. Once the implants were dissolved, 5 ml ethanol was
added to completely dissolve curcumin. The solution was then diluted suitably (1:10)
with ethanol containing 20% DCM followed by in ethanol (1 in 40). Drug concentration
was measured by UV spectrophotometer at 430 nm to calculate the amount of curcumin
released in vivo using following equation:
Average Daily Release

Initial amount - Residual amount
Time (days)

Analysis of Plasma and Tissue Curcumin Levels
Plasma pooled from all the animals (1.5 ml) was mixed with 200 III of 0.5 M sodium
acetate to reduce the pH to 5. Plasma was then extracted thrice with 3 ml ethyl acetate.
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Ethyl acetate extracts were pooled and dried under vacuum. The dried residue was
reconstituted in 100 III of acetonitrile (ACN), one half of the solution was analyzed by
HPLC to determine the plasma concentration. Similarly, liver or brain tissue (-500 mg)
from each animal was homogenized in 3 ml PBS (pH 7.4) containing 200 III of 0.5 M
sodium acetate. The homogenate was then extracted twice with 2 volumes of ethyl
acetate. After evaporation of ethyl acetate under vacuum, the residue was reconstituted
in 1 ml ACN. The solution was filtered through 0.45 11 glass-microfiber filter and
evaporated again under vacuum. The residue was finally reconstituted in 100 III ACN
and one half of it was analyzed by HPLC using Shimadzu liquid chromatography system
equipped with LC-10ADVP pump, RF-1 OAXL fluorescence detector and a Shimadzu C 18
column of 5 11m particles (250 x 4.6 mm). The three curcuminoids were separated by
using ACN and 1% citric acid (adjusted to pH 2.5) at a flow rate of 1 ml/min with a
gradient elution in which ACN concentration was increased from 0 to 30% in first 5 min,
followed by an increase to 45% in next 5 to 20 min. ACN was then maintained at this
ratio till 36 min. Curcuminoids were detected using 410 and 500 nm as excitation and
emission maxima, respectively, in the fluorescence detector.

Microsome Extraction
Liver (-100 mg) was homogenized in 0.25 M sucrose buffer (pH 7.4) at 3,000 rpm with
Polytron. The homogenate was centrifuged at 3,000 g for 20 min at 4 DC to separate the
nuclear content. The supernatant was collected and again centrifuged at 11,000 g for 20
min at 4 DC to separate the mitochondria. The post-mitochondrial supernatant was then
transferred to ultracentrifuge tubes and finally centrifuged at 100,000g for 1 h at 4 DC to
separate the microsomes. The pellet was suspended .in 1 ml sucrose buffer, aliquoted
and stored at -80 DC until use.
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Analysis of Cytochrome P450s and GSTIJ (GSTM)
Microsomal proteins were quantified using bicinchoninic acid (BCA) method (120) using
BCATM Protein Assay kit (Thermo Scientific, Rockford, Il) and were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SOS-PAGE) on a 10% gel. Protein
bands were then transferred to polyvinylidene diflouride (PVOF) membrane which was
incubated with 5% non-fat dried milk in Tris-buffered-saline for 1 h at room temperature
(25 DC) to block the non-specific binding sites. The membrane was then incubated with
primary antibodies for CYP1A1 and GSTM, followed by horseradish peroxidase
conjugated

secondary

antibody.

The

bands

were

detected

by

enhanced

chemiluminescence using Pierce® ECl Western-Blotting Substrate (Thermo Scientific,
Rockford, Il) and quantified using VersaOoc Imaging System (BioRad laboratories,
Hercules, CA).

Determination of CYP3A4 Activity
CYP3A4 activity was measured using P450-GloTM CYP3A4 assay with luciferin-IPA
(Promega Corporation, Madison, WI) following manufacturer's protocol by replacing
NAOPH regenerating system with NAOPH (5 mM).

Statistics
All groups were compared by students T test for statistical significance. Blank implants
and curcumin diet groups were compared with untreated controls and curcumin implants
were compared with blank implants for all statistical purposes at a significance level of p
value <0.05 (n=3-4).
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Results and Discussion
This specific aim was designed (i) to analyze the in vivo release of curcumin from
polymeric implants, (ii) to derive an in vitro-in vivo correlation of drug release, (iii) to
compare the tissue distribution of curcumin delivered via these implants with curcumin
delivered via diet and finally (iv) to compare preliminary efficacy of curcumin delivered
via both routes by measuring modulation of hepatic cytochrome levels. Therefore, to

achieve these objectives, various in vivo release studies were done by subcutaneously
implanting two 2-cm implants (10% or 20% w/w drug load either with F-68 (10%) or PEG
(35%)) beneath the skin of female ACI rats and were recovered after predetermined time
intervals by sacrificing the animals.

In Vivo Drug Release Studies
Effect of Drug Load
To study the effect of curcumin drug load on in vivo release, implants with 10 and 20%
drug loads were implanted at the back of female ACI rats and were recovered after
specific time intervals to measure the residual drug load, shown in Figure 3.1. The drug
release was found to be diffusion mediated and increased with drug loading as observed
under in vitro conditions. These studies showed that initially -377±52 Ilg/day drug was
released over a period of 1 week with 10% drug load which dropped to -292±59 Ilg/day
over a period of 3 weeks. However, from implants with 20% drug load, -666±160 Ilg/day
was released initially which reduced to -294±110 Ilg/day after 3 weeks. The drug
release was -1.7 times higher during first week from 20% drug load implants as
compared to 10% drug load (Figure 3.2). Since initial burst release is from the surface
adsorbed drug which is proportional to the drug load, it was higher with high drug load
implants (111). However, as the drug release started from inner polymeric layers;
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diffusion mediated and drug load independent release was observed as was found
under in vitro release studies (111).
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Figure 3.1. Average daily in vivo drug release from 2-cm implants with 10 and 20% drug load.

--

14

~ 10%

_

~12

Drug Load

20% Drug Load

CD

1n10

ca

~

CD

a::

8

CD

> 6
ca

'';;

:::::I

E 4
:::::I

0

2
0
0

5

10

20

15

25

30

35

40

Days
Figure 3.2. Cumulative in vivo drug release from 2-cm implants with 10 and 20% drug load .
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Effect of Water Soluble Additives
It was observed under in vitro conditions that presence of PEG (35% w/w) increases the
drug release as compared to that of F-68 (10% w/w). Therefore, to determine the effect
of these water soluble additives, in vivo drug release was also studied from implants
containing 20% drug load prepared either with 10% F-68 or with 35% PEG. In vivo
release from F-68 implants was studied for a period of 16 months (70 weeks) (table 3.1)
and from PEG for 6 months (table 3.2). In vivo release was found to reveal similar
pattern as was observed under in vitro conditions with slightly higher release from PEG
(35%, w/w) implants as compared to F-68 (10% w/w) implants both during initial burst

phase as we" as during 2nd controlled release phase. It appears that PEG being highly
water soluble not only increases the hydrophilicity of the polymeric matrix but also
provides a more porous microstructure that results in enhanced water permeation into
the matrix (117) and hence increased release at such high PEG levels (35% w/w).

Furthermore, in vivo release was observed to mimic the in vitro release with a burst
release of -1,800 I1g on day 1 which rapidly declined to -380 I1g on day 4 after which
more stable release kinetics were observed with implants prepared with 35% PEG. Drug
release was found to be 300-350 I1g/day for over a period of 1 month and then reduced
to -130 I1g/day after 3 months. Cumulative in vivo release was -30% after 1 month
which was -1.8-2 fold higher than in vitro release suggesting a good correlation between
simulated in vitro and in vivo conditions. Furthermore, only -50% (19 mg out of 38.2 mg
determined in initial implants) drug was found to be released from these implants over a
period of 3 months showing their potential to deliver curcumin for extended periods of
time ranging from 6 months to a year.
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Table 3.1.
Cumulative in vivo curcumin release from im!2lants containing 20% (w/w) drug load and 10% (w/w) F-68 for a !2eriod of 16 months.
Cumulative Drug Release (%)

Cumulative Drug Release (mg)
Weeks
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4.66

1.12

15
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9
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825.02

669.72 504.06

666.27

160.51

2

14

6.74

8.00

7.28

7.34
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18

21
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2

295.91

476.61

374.31

382.28

90.61

3

21

10.26

8.75

9.18

9.40

0.78

27
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2

417.19

202.06 262.89

294.05

110.90

5

35

12.37

12.07

12.22

0.21

0

32

32

21

19

8

56

15.03

15.90

15.04

15.32

0.50

39

42

39

40

18

126

20.61

17.40

18.81

18.94

1.61

54

46

49

50

36

252

23.67

24.62

23.84

24.05

0.51
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65

63

42

294

24.87

25.58

25.22

0.50

65

70

490

28.67

28.63

28.85

0.35

75

29.25

77

211.95

190.69 201.32

15.03

134.01

175.21

134.49

147.90

23.65

75.47

29.69

49.82

51.66

22.95

63

37.59

45.12

38.89

40.53

4.02

67
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19.55

36.47

28.01

11.96

75
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17.57

17.41

18.51

1.77

4

20.55

Table 3.2
Cumulative in vivo curcumin release from im!2lants containing 20% (w/w) drug load and 35% (w/w) PEG for a !2eriod of 6 months.
Cumulative OruS Release ~ms~

Averase Oail~ Release <l:!S>

% Cumulative OruS Release

Oa~s

Im~1

Im~2

Im~3

Mean

SO

Im~ 1

Im~2

Im~3

Mean

SO

Im~1

Im~2

Im~3

Mean

SO

1
4
12
25
90
138
184

2.23
2.65
5.84
10.91
18.84
23.04
24.53

1.44
2.49
6.05
10.75
19.39
24.73
25.37

1.75
3.51
7.80
11.00
18.91
23.03

1.8
2.9
6.6
10.9
19.0
23.6
25.0

0.4
0.5
1.1
0.1
0.3
1.0
0.6

5.8
6.9
15.3
28.5
49.2
60.2
64.1

3.8
6.5
15.8
28.1
50.6
64.6
66.2

4.6
9.2
20.4
28.7
49.4
60.1

4.7
7.5
17.1
28.4
49.7
61.6
65.1

1.0
1.4
2.8
0.3
0.8
2.6
1.5

2230.0
282.2
368.1
331.3
124.1
82.4
58.3

1440.0
230.7
393.4
319.3
132.6
117.0
67.0

1750.0
568.7
612.3
338.7
125.1
82.2

1806.7
360.6
457.9
329.8
127.3
93.9
62.7

398
182
134
10
5
20
6

Tissue Distribution of Curcumin
Tissue concentrations of curcumin delivered either by implants or by dietary routes were
also measured in plasma, liver and brain. For these studies, female ACI rats were either
implanted with two 2-cm implants (200 mg, 20% drug load) or were administered with
diet containing curcumin (1,000 ppm). The animals were sacrificed after 1, 4, 12, 25 and
90 days and various tissues (plasma, liver and brain) were collected. Curcumin was
extracted from the tissues using solvent extraction and analyzed using HPLC coupled
with a fluorescence detector with an extraction efficiency of -90% from plasma and
-70% from tissues (liver and brain). Fluorescence detector was used due to very high
fluorescence of curcumin which not only increased the specificity of curcumin detection
but also increased the sensitivity by at least 4-5 fold. The lower limit of detection in
plasma was found to be 125 pg (340 pM) and limit of quantification was -200 pg (540
pM) by this method.

When -500 III of plasma was extracted from each individual animal and analyzed by
HPLC, the levels were found to be very low and were below the quantification limit of the
method. Therefore, to increase the specificity and reliability of quantification, the
extraction was performed with 1.5 ml plasma by pooling 250-350 III of plasma from all
the animals (4-6 in each group) (Figure 3.3). The plasma curcumin levels from the
implants group were found to be 3.3 ng/ml (9 nM) on day 1 which decreased rapidly to
1.4 ng/ml (4 nM) on day 4 after which a slow and steady decrease in plasma
concentration was observed reaching -0.2 ng/ml (543 pM) after 3 months. Curcumin diet
on the other hand, showed different kinetics in that curcumin was detected only on day 4
at a level of 0.3 ng/ml (815 pM) decreasing to 0.2 ng/ml after 12 days (543 pM) and was
undetectable after 25, and 90 days. It was highly counter intuitive that instead of the fact
that curcumin diet consumption was constant at all the time periods, curcumin was not
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observed on day 1 and a decline in plasma curcumin concentrations was observed on
day 4 suggesting time- and exposure-dependent absorption kinetics. Furthermore,
curcumin due to its lipophilic nature exhibits biphasic elimination kinetics with rapid
equilibration and distribution of plasma curcumin into various tissues (121). It is,
therefore, also possible that due to high tissue distribution of curcumin, initially almost all
curcumin equilibrates into tissues and was not observed in plasma on day 1. However,
with time as the lipophilic tissues gets saturated, curcumin was observed in plasma after
4 days on dietary administration.
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Figure 3.3. Curcumin levels in the plasma of ACI rats treated with curcumin implants (two 2-cm
implants; 20 mg curcumin/cm) or curcumin diet (1,000 ppm). One and half ml plasma was
extracted from each time point after pooling and analyzed by HPLC using fluorescence detector
as described under methodology.

It is known that curcumin possess poor oral bioavailability owing to its low aqueous
solubility (24) and rapid metabolism both in intestine as well as in liver (12, 122).
Therefore, to further understand the kinetics of curcumin delivered via both the routes,
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its concentration in liver was also measured (Figure 3.4). Curcumin delivered via both
routes was found to be at similar levels in liver and was 25-30 ng on day 1. The levels
increased slightly, though insignificantly on day 4 after which the levels declined to 10-15
ng after 12 days. This trend was found to exactly mimic the plasma concentrations
suggestive of hepatic regulation of plasma curcumin levels at least via dietary route.
Curcumin is known to induce the expression and activity of various enzymes like
CYP1 A 1 (123), GSTM (124), CYP3A4 (125) and it appears that significant amounts of
curcumin that reaches the liver tissue induce its own metabolism by increasing the
expression/activity of these xenobiotic metabolizing enzymes. The levels, therefore,
decreases significantly after 12 days and stayed almost constant afterwards.
Furthermore, curcumin concentration was found to be much higher (10-20 fold) in liver
as compared to plasma via both routes again suggestive of its high tissue distribution.
High curcumin concentrations in hepatic tissues via dietary administration were expected
as most of the orally administered curcumin gets absorbed into the liver where it
undergoes rapid metabolism. However, similar behavior from the implant route was
unexpected as it bypasses the hepatic first-pass metabolism and almost all of the
administered curcumin directly reaches into the systemic circulation. Therefore, a much
higher concentration was expected in plasma from implant route. It appears that such a
pharmacokinetic behavior also originated from curcumin's high lipophilicity resulting in
high tissue distribution as compared to plasma. Moreover, since phYSiologically liver is a
highly perfused organ and gets around 23% of total cardiac output, it is highly probable
that most of the curcumin that reaches into the systemic circulation might get rapidly
equilibrated and entrapped into the liver tissue. An almost constant liver concentration of
curcumin from 12 to 90 days also suggests tissue binding of this compound.
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Figure 3.4. Liver curcumin levels in ACI rats treated with curcumin implants (two 2-cm implants,
20 mg/cm implant) or curcumin diet (1,000 ppm). Tissue (-500 mg) from individual animal (n =46) was extracted and analyzed by HPLC coupled with a fluorescence detector as described in
methodology.

To support these observations, we further analyzed curcumin concentration in the whole
brain tissue as it is also one of the highly perfused organs. Brain was also selected
because of curcumin's known potent activities against Alzheimer's disease (126) and
against brain gliomas (127) where continuous localized/systemic delivery of this
compound could make a significant improvement in the life of such patients. Analysis of
brain tissue showed almost constant levels of curcumin (2-3 ng/g) from dietary
administration at all the time points (Figure 3.5.). Although, curcumin was not found in
plasma on day 1 in the dietary curcumin group, it indeed was present in brain. This
observation further supports the fact that initially all the curcumin that escaped from liver
and reached the systemic circulation partitioned into highly lipophilic sites like liver and
other tissues. However, as equilibrium is established between plasma and other organs
like brain, curcumin started to accumulate in plasma and could be detected after 4 days
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of oral administration. Furthermore, constant curcumin levels in brain detected even after
90 days again suggests increased metabolism of curcumin in liver tissues that led to
decreased curcumin concentration in liver at 12 days.
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Figure 3.5. Brain curcumin levels in ACI rats treated with curcumin implants (two 2-cm implants,
20 mg/cm) or dietary curcumin (1,000 ppm). Tissue (-500 mg) from individual animals was
extracted and analyzed by HPLC coupled with a fluorescence detector. Data represent average
of 4-6 animals, except for day 1 where data represents average of two animals since curcumin
was below the detection limit in the remaining animals.

On the other hand, curcumin delivery to the brain via implant route showed kinetics
similar to plasma. Since, drug concentration that reaches a tissue is determined by rate
and extent of its perfusion by systemic circulation, brain showed rather high curcumin
levels (30±7.3 ng/g tissue), almost equal to liver concentration on day 1 of implantation.
This concentration dropped slowly to around 7.26±2.45 ng/g tissue after 12 days and
stayed almost at the same levels even after 90 days which was slightly less than the
liver concentration from 12 to 90 days (a constant drug concentration period). It is known

72

that physiologically, liver gets -23% of cardiac output and brain gets slightly less than
liver (-18%). This fact again shows that tissue distribution from implant route was indeed
perfusion rate limited and is dictated by cardiac output to that particular organ. It may be
emphasized that curcumin concentration in the brain tissue was -3.5-fold higher by the
implant route in which case total curcumin administered was nearly 25 fold lower
compared to oral administration over a period of 3 months.

Analysis of curcumin in different tissues showed that plasma curcumin concentration via
dietary administration is regulated by liver. At high liver concentration, a fraction of
dietary curcumin escapes hepatic first pass metabolism into the systemic circulation and
gets distributed to other organs. Tissue concentration is then determined by extent of
blood supply to the respective organ. However, this is not the case with the implant route
where plasma is the first site of curcumin absorption from where it gets simultaneously
distributed to all the other tissues. Tissue concentrations are, therefore, determined only
by the extent and rate of blood that supplies the organ. In view of these facts, it is
possible that to administer curcumin to other organs like prostate or pancreas which are
not richly supplied with blood, dietary administration might not be an appropriate route.
In such cases, direct systemic administration either via parenteral routes or via implant
route would be a better alternative that can be further evaluated for various preclinical
and clinical studies.

Modulation of Phase I and Phase II Enzymes
CYP1A1 and GSTM (J.I) Expression Analysis in Hepatic Microsomes
Various in vitro and cell culture studies showed that curcumin's effective concentration is
5-20 11M depending upon the cell line used (128). Since the plasma and liver
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concentrations observed in our in vivo study (70-90 nM) were well below these, we also
determined if these concentrations modulated hepatic cytochromes. Studies have shown
that curcumin is a natural agonist of aryl hydrocarbon receptor (AhR)/pregnane
xenobiotic receptor (PXR) pathway and induces the expression of phase I enzymes like
CYP1 A 1 (123) and CYP3A4 (125). Furthermore, it also interacts with the keap1 protein
to lower its affinity for nuclear factor (erythroid-derived 2)-like 2 (Nrf2) protein followed by
Nrf2 transloaction into the nucleus to induce phase II enzymes like glutathione-Stransferase(ll) (GSTM) (124). Therefore, we isolated hepatic microsomes and analyzed
them for their CYP1 A 1, CYP3A4 and GSTM levels by western blotting and activity of
CYP3A4 (a major drug metabolizing enzyme) after 1,4, 12,25 and 90 days of curcumin
treatment by both dietary and implant routes.

As is evident from the Figure 3.6, curcumin implants were found to induce expression of
CYP1 A 1 by -2 fold after 4, 12, 25 and 90 days of treatment. Although, a 2 fold increase
in CYP1 A 1 was observed on day 1, yet the effect was masked by PEG as a similar
effect was also observed in blank implants at this time point and this effect from the
blank implants was absent at all other time points. This effect from blank implants was
presumably due to release of significant amounts of PEG on day 1 which decreased
significantly on day 4 (PEG release was measured by subtracting the amount of
released curcumin and weight of dried implant recovered from animals from initial weight
of the implants) (129). Curcumin diet, on the other hand, increased CYP1A1 levels only
Slightly on day 1 (1.43 fold) which returned to basal levels after 4 days and in-fact the
levels were down-regulated after 25 and 90 days of treatment. Since, the hepatic
curcumin levels were similar by both the routes tested; such route-dependent differences
in induction of CYP1 A 1 expression were counter intuitive. It is known that various
chemopreventives like indole-3-carbinol (13C) are most effective in inducing CYP1 A 1
74

when given orally as compared to when given systemically (130). It has been found that
polymerization products of indole-3-carbonol like diindolylmethane formed under
stomach acidic conditions are more effective AhR ligands as compared to the parent
compound, thus resulting in higher efficacy of indole-3-carbinol (130). Curcumin is also
known to degrade under slightly basic conditions of intestine forming various active
degradation products like ferulic acid and vanillin (92). It is possible that one or more of
these metabolites might have AhR antagonistic activity resulting in blunting of curcumin's
CYP1A1 upregulating activity at initial time points and eventual downregulation after 25
and 90 days of treatment. GSTM, on the other hand was not modulated via either of the
routes (data not shown).
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Figure 3.6. Effect of curcumin administered by polymeric implants (two 2-cm implants, 20 mg/cm)
or diet (1,000 ppm) on CYP1A1 protein expression in hepatic microsomes of ACI rats. Blank
implants and curcumin diet groups were compared with untreated controls and curcumin implants
were compared with blank implants for all statistical purposes at a significance level of p value
<0.05 (n=3-4).
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CYP3A4 Activity and Expression Analysis in Hepatic Microsomes
Effect of curcumin on CYP3A4 activity was also measured as it is the major drug
metabolizing enzyme known to get induced by curcumin (Figure 3.7) (125). CYP3A4
activity was found to be increased significantly by curcumin diet after 4 days but came to
basal levels after 12 days of treatment. Curcumin implants, on the other hand, were
found to increase the activity only slightly on both day 1 and day 4 of treatment. However
this increase became significant after 12 days of treatment and remained upregulated up
to 3 months. This increase was not found to blunt with time and increased activity was
found up to 3 months. It appears that continuous delivery of curcumin directly into the
systemic circulation by the implant route was more effective in increasing and
maintaining the higher CYP3A4 activity as compared to dietary route.
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Figure 3.7. Effect of curcumin administered by polymeric implants (two 2-cm implants, 20 mg/cm)
or diet curcumin (1 ,000 ppm) on CYP3A4 activity in hepatic microsomes of ACI rats. Blank
implants and curcumin diet groups were compared with untreated controls and curcumin implants
were compared with blank implants for all statistical purposes at a significance level of p value
<0.05 (n=3-4).
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Conclusions
These studies showed that polymeric implants on subcutaneous implantation can
provide a controlled release of curcumin at the local site from which it gets absorbed into
the systemic circulation and gets distributed to all the tissues simultaneously. These
implants were found to provide higher curcumin concentrations in plasma, brain and to
some extent in liver over a period of 3 months as compared to dietary administration.
Furthermore, curcumin delivered directly into the systemic circulation was found to be
more efficacious in inducing CYP1 A 1 and CYP3A4 enzymes required for its
chemopreventive activity against various environmental carcinogens. Presence of
significantly higher concentrations of curcumin in tissues like brain shows potential of
this delivery system for patients suffering with Alzheimer's disease and/or brain gliomas
where curcumin has shown significant potential in various in situ and cell culture studies
but does not reach in sufficient amounts by dietary route.
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CHAPTER IV
CURCUMIN IMPLANTS FOR CONTINUOUS SYSTEMIC DELIVERY: SAFETY
AND BIOCOMPATIBILITY

Rationale
Biomedical implants, once implanted subcutaneously, come in contact with blood and
tissues often initiating immunological reactions by activating cellular and humoral
immune responses. This is a surface phenomenon, characterized by various cell
polymer, protein-polymer and cell-cell interactions. Although, poIY(E-caprolactone) (PCl)
is an FDA-approved, biocompatible polymer for use in humans (104) and its
contraceptive implants are in phase II clinical trials in China (131), various implant
attributes like implant shape, size, surface roughness, porosity, composition and nature
of degradation all contribute towards the intensity and duration of tissue reactions (132).
Therefore, determination of biocompatibility and immunological safety of these PCl
implants containing 35% polyethylene glycol, molecular weight 8,000 (PEG) is another
criterion for selection of suitable implant candidates for further evaluation under
preclinical and clinical studies. Moreover, although curcumin was not found to induce
any observable toxicity when given orally to patients and was well tolerated in doses 812 g (133), its toxic effects on direct systemic administration of high doses are unknown.
However, recently Dandekar et al. (134), showed safety of oral curcumin NPs made by
using Eudragit® S 100 but the studies were done by oral administration and does not
provide insights about the systemic administration of curcumin. Since, polymeric

78

curcumin implants release -300-500 Ilg/implantlday curcumin directly into the systemic
circulation at least initially for 2-3 weeks (135), we wanted to determine if subcutaneous
administration of such high quantities of curcumin exert any biochemical alterations in
body by altering liver and kidney functions. Therefore, this study was designed to
examine the systemic and local effects of the polymeric implants formulated with and
without curcumin. Blood clinical chemistry, various hematological parameters and
systemic biochemical parameters of liver and kidney function were monitored to assess
the safety, tolerability and biocompatibility of implants. Local site of implantation was
also evaluated histologically to determine the degree and extent of inflammation induced
by these implants as well as by systemic delivery of high doses of curcumin to determine
their biocompatibility and acceptability by the body.
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Materials and Methods
Materials
Medical grade PCl of 121,000 molecular weight (PCl) was purchased from SurModics
Pharmaceuticals (Birmingham, Al). Oichloromethane (OCM) was purchased from
Sigma-Aldrich (St. louis, MO), polyethylene glycol of 8000 molecular weight (PEG) from
Fisher Scientific (Fair lawn, New Jersey), and ethanol from Pharmco-AAPER (louisville,
KY). Silastic tubing (3.4 mm internal diameter) was purchased from Allied Biomedical
(Ventura, CA). Curcumin (C-3 complex) extracted under GMP conditions (good
manufacturing practices) was a generous gift from Sabinsa Corporation (East Windsor,
NJ). All the materials were used as received without any further analysis.

Methods
Preparation of Curcumin Implants
Curcumin implants were prepared by using a combination of solvent evaporation and
melt-extrusion technique as described in chapter 2. Briefly, curcumin was dissolved in
ethanol and polymers (PCl with PEG in a ratio of 65:35) were dissolved in OCM. Two
solutions were then mixed together and solvents were evaporated at 70 °c to prepare a
homogenous molecular dispersion of drug in polymeric matrix followed by overnight
drying under vacuum at 65°C. The dried molten polymer was extruded through silastic
tubing attached to a syringe. After few min, the cylindrical implants were removed from
the tubing and excised into desired lengths (2 cm, 200 mg with 20 mg curcumin/cm) and
stored at -20 °c under argon until used.
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In Vivo Studies
In vivo release, biocompatibility and toxicity studies were performed in female ACI
(Augustus Copenhagen Irish) rats in accordance to an approved protocol from the
Institutional Animal Care and Use Committee (lACUC). Animals were provided with
purified diet; AIN-93M and water ad libitum until termination of the study. After
acclimation of animals to vivarium conditions, either two 2-cm implants with or without
(sham implants) 20% (w/w) curcumin (20 mg/cm) were subcutaneously grafted at the
back of the rats as described previously (119) or were provided with curcumin (1,000
ppm) mixed with diet. Animals were euthanized at different intervals by asphyxiation to
collect blood (by cardiac puncture), liver, local tissues and implants from the implantation
site. Implants recovered from the animals were dried overnight under vacuum, weighed
and stored under argon at -80°C until analysis of the residual curcumin content. A small
portion of liver from the biggest lobe and a portion of tissue from the site of implantation
were fixed in formalin and the remaining tissues were snap frozen in liquid nitrogen and
stored at -80°C for future use. Whole blood was used to measure the hematological
parameters by Cell-Dyn 3500 hematology analyzer (Abbott laboratories, Santa Clara,
CAl which employs Multi-Angle Polarized Scatter Separation technique to provide
primary white blood cell count, reticulocyte analysis and all differential counts. Serum
was used to measure various biochemical parameters of liver and kidney function by
using an automated AU640® Chemistry Analyzer (Beckman Coulter, Inc. Brea, CAl that
uses an ion selective electrode to measure various electrolytes and in built
spectrophotometric techniques for all other assays. These assays were done in a local
diagnostic lab maintained and run by Antech Diagnostics.

81

Residual Drug Determination
Implants (n=3) collected after 1, 4, 12, 25 and 90 days at the time of euthanasia were
analyzed to determine the residual drug content, as described in chapter 3.· Briefly,
implants recovered from animals were dried over night under vacuum, were weighed
and dissolved in 5 ml DCM. To this solution 5 ml ethanol was added to completely
dissolve curcumin. The solution was then diluted suitably (1: 10) with ethanol containing
20% DCM followed by in ethanol (1 in 40). Drug concentration was measured by UV
spectrophotometer at 430 nm to calculate the amount of curcumin released in vivo using
following equation:
Initial amount - Residual amount

Cumulative curcumin release =

Days

Histology studies
Tissues, collected in 10% buffered formalin, were transferred to 70% ethanol and
processed at the University's core histology facility. Paraffin sections of 5-llm thickness
were cut and stained with hematoxylin and eosin. Slides were blinded and observed
under light microscope by an experienced cytopathologist.

Statistics
Two way Anova with Bonferroni post-test was used to calculate statistically significant
differences between the various interventions and a p value of <0.05 was considered as
significant.
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Results and Discussion
Acute and chronic local/systemic toxicity was studied by subcutaneously implanting two,
cylindrical PCl-PEG implants (200 rrig each) with or without curcumin for a period of 3
months.

Systemic toxicological

effects were determined by measuring various

hematological parameters, serum biochemical parameters of liver & kidney function and
the local effects of implantation were evaluated by histological examination of the
implant site. After specific time intervals (1, 4, 12, 25 and 90 days), 4-5 animals from
each group were euthanized, blood/serum was collected by cardiac puncture and
analyzed for various biochemical parameters to determine the effects of polymeric
implant formulation (sham implants) and of continuous administration of curcumin
delivered directly into the systemic circulation by these implants. Gross examination of
liver, lung, kidney, brain and pituitary was also carried out at the time of necropsy and
were weighed to determine any differences as compared to untreated animals.

All rats in the study were found to be healthy and active without any evident pathological
manifestations irrespective of the kind of treatment given during the whole period of
study. However, pre-necroptic palpation of animals showed slightly thickened areas over
the implant sites without any apparent effect on hair growth and texture. No statistically
significant differences were found either in diet intake (Figure 4.1) or in weights of
different organs (liver, lung, kidney, brain, pituitary and mammary tissue) over a period of
3 months. However, a reduction in body weight gain was observed in animals treated
with curcumin either via implants or via diet (Figure 4.2). Curcumin has been shown to
possess hypoglycemic (136) and hypocholesterolemic activities (137) and it appears that
curcumin when delivered via either route was able to exert these activities.
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Figure 4.1 . Diet intake of animals treated with either curcumin diet (1,000 ppm), sham implants or
with curcumin implants as compared to animals given control diet AIN-93M.
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Figure 4.2. Body weight gain of animals treated with either curcumin diet (1,000 ppm), sham
implants or with curcumin implants as compared to animals given control diet; AIN -93M.
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Cumulative Drug Release
Since the polymeric implant drug delivery system enabled us to continuously deliver high
quantities of curcumin directly into the systemic circulation, we determined the amount of
curcumin released under in vivo conditions by measuring the residual amount of drug in
implants recovered from animals. It was found that a total of 3.6 ± 0.8 mg of curcumin
was released from both the implants combined (4.5% of total drug load from each
implant) on day 1 of implantation and increased to 5.8 ± 1.1, 13.1 ± 2.1, 21.8 ± 0.3, 38.1
± 0.6, 47.2 ± 1.6 mg after 4, 12, 25 and 90 days respectively (Figure 4.3).
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Figure 4.3. Cumulative curcumin release from two 2-cm implants (200 mg with 40 mg drug in
each) grafted in female ACI rats. Data represent twice the average release from implants
recovered from 3-4 animals (±SD).

Since curcumin released from implants at the site of implantation gets absorbed into the
systemic circulation, it is clear that high amounts of curcumin entered into blood and got
distributed to various tissues. Since, liver and kidney are the highly perfused organs
specific for elimination of xenobiotic compounds and are highly sensitive to xenobiotic
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insults; we measured various (enzyme and electrolyte) indicators of liver and kidney
function at different time intervals after treatment with curcumin implants and compared
them with curcumin diet (1,000 ppm).

Effect on Liver Enzymes
AST, AlT, ALP, GGT, amylase and lipase levels were measured in serum of animals
treated either with two 2-cm pel implants (200 mg) containing PEG (35% w/w) alone
(sham implants) or curcumin (20% load) with PEG (35% w/w) or curcumin diet (1,000
ppm) after 1, 4, 12,25 and 90 days and were compared with untreated animals (Figure
4.4). Sham implants were found to decrease serum amylase levels after 1 day of
implantation; however, this decrease was transient and returned back to normal levels
after 4 days. Since sham implants contained 35% PEG which is a highly water soluble
polymer, it appears that this transient increase in lipase levels might be due to release of
high amounts of PEG into the systemic circulation on day 1 of implantation. This effect
was neither found with curcumin delivered via implants suggestive of curcumin's
hepatoprotective activity (138, 139) nor by dietary curcumin. Furthermore, no statistically
significant effect was found on any of the other serum enzymes analyzed, with any of the
treatments.
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Figure 4.4. Various enzymes measured in serum of female ACI rats after subcutaneous
implantation of two 2-cm polymer alone blank implants (sham implants containing PCL:PEG,
65:35), implants containing curcumin (40 mg each) and curcumin given in diet (1,000 ppm) after
(a) 1 day, (b) 4 days , (c) 12 days and (d) 3 months; samples from 25 days were not analyzed.

Serum from animals was also analyzed for plasma proteins (albumin and globulin) as
well as for effects on glucose, cholesterol and triglycerides (Figure 4.5.). Serum albumin
levels were found to be slightly higher for sham implants and for curcumin diet after 12
days of treatment. However, this increase was not observed either at 4 or 25 days
treatment or with curcumin implants. Furthermore, there was only 8.6% increase in
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albumin levels and was well within the normal physiological range to indicate any major
pathological conditions.
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Figure 4.5. Plasma Proteins (albumin and globulin) , glucose, cholesterol and triglycerides
measured in serum of female ACI rats after subcutaneous implantation of two 2-cm polymer
alone blank implants (sham implants containing PCL:PEG , 65:35) , implants containing curcumin
(40 mg each) and curcumin given in diet (1 ,000 ppm) after (a) 1 day, (b) 4 days, (c) 12 days and
(d) 3 months ; samples from 25 days treatment were not analyzed.

The most apparent effect of curcumin intervention was found to be on serum glucose
levels. Curcumin delivered either via implants or in diet significantly reduced serum
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glucose levels (188 ± 22 mg/dL and 172 ± 9 mg/dL, respectiverly) at 4 days of treatment
compared to sham implant treatment (245 ± 22 mg/dL) or to untreated animals (289 ± 76
mg/dL) consistent with curcumin's anti-diabetic activity (136). Analysis of liver curcumin
concentration delivered by both routes showed that curcumin levels increased slightly
from 1 to 4 days (78 nM to 95 nM; assuming density of liver to be equal to 1), although
not significantly, after which it decreased drastically at 12 days of treatment (35 nM) and
was almost constant for up to 90 days. Since this effect was not observed either at 1 day
or after 12 days of treatment, it appears that curcumin concentrations were high enough
at 4 days to exert anti-diabetic effects and were low both at 1 day and 12 days of
treatment. Furthermore, although TG levels were unchanged at all the time points
shown, we have seen significant reduction of TG levels by curcumin both via implants
(93 ± 22 mg/dL) and via diet (80 ± 27 mg/dL) after 6 months of treatment as compared to
with sham treatment (166 ± 54 mg/dL) or with untreated control animals (143 ± 45
mg/dL). Both these observations suggest the usefulness of curcumin as an effective
anti-diabetic as well as a hypocholesterolemic agent consistent with previous reports
(137).

Effects on Serum Electrolytes/Kidney Function
Kidney function was analyzed by measuring blood urea nitrogen (BUN), creatinine and
various electrolytes in serum (Figure 4.6). A transient increase in Mg2+ by curcumin diet
and in K+ by sham implants was observed after 1 day of treatment and were normal at
all the other time points. Both these effects were not observed with curcumin implants.
A more consistent alteration in phosphorus levels was also observed at all the time
points studied. Phosphorus in serum of all the treatment groups; sham implants,
curcumin implants and curcumin diet was found to be significantly elevated at all the
time points. It is unclear at this point whether this effect is due to disturbances in
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phosphorus absorption , storage or excretion and requires further investigation to
determine the underlying cause(s).
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Figure 4.6. Various metabolites and electrolyte indicators of kidney function measured in serum of
female ACI rats after subcutaneous implantation of two 2-cm polymer alone blank implants (sham
implants containing PCL:PEG , 65:35), implants containing curcumin (40 mg each) and curcumin
given in diet (1 ,000 ppm) after (a) 1 day, (b) 4 days, (c) 12 days and (d) 3 Months ; samples from
25 day treatment were not analyzed.

Effect on Hematological Parameters
Whole blood from untreated and treated animals was also analyzed for various
hematological parameters like white blood cells (WBCs), red blood cells (RBCs) ,
hemoglobin (HGB) , hematocrit (HCT), mean corpuscular volume (MCV) , mean
corpuscular hemoglobin (MCH) , mean corpuscular hemoglobin concentration (MCHC)
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and platelet count (Figure 4.7). No significant changes were observed in any of these
parameters, except a slight decrease in platelet count and WBC count with curcumin diet
at 4 days and 12 days time points, respectively. However, these effects were not
observed either with sham or with curcumin implants at any of these time points.
Moreover, platelet and WBC counts were found to be well within the baseline range of
untreated animals over 90 days time period suggesting absence of any significant
toxicity of PCl implants and hence of curcumin delivered via these implants.
_
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Figure 4.7. Various hematological parameters measured in blood of female ACI rats after
subcutaneous implantation of two 2-cm polymer alone blank implants (sham implants containing
PCL:PEG , 65 :35) , implants containing curcumin (40 mg each) and curcumin given in diet (1,000
ppm) after (a) 1 day, (b) 4 days, (c) 12 days and (d) 3 months.
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Furthermore neutrophils, lymphocytes, monocytes, eosinophils and basophils were also
analyzed in the whole blood. Although, no significant alterations were observed in
monocytes, eosinophils and basophils, significant effects were observed in neutrophil
and lymphocyte levels both with sham and curcumin implants at certain time points as
compared to untreated animals (Figure 4.8). Therefore, to obtain a more realistic picture
of fluctuations of these parameters in blood, both neutrophils and lymphocytes were
analyzed by logistic transformation (Figure 4.9) as was suggested by Laurencin et al.
(140). Logistic transformation was done to approximate the error distribution of
measured values with the Gaussian reference distribution, using the following relation:
Neutrophils

= In[% Neutrophils/1-%Neutrophils],

and
Lymphocytes

= In[% Lymphocytes/1-%Lymphocytes]
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Figure 4.8. Neutrophil and lymphocyte counts (/111) measured after 1, 4, 12 and 90 days in blood
of (a) untreated female ACI rats or (b) after subcutaneous implantation of two 2-cm polymer alone
blank implants (sham implants containing PCL:PEG, 65:35), (c) implants containing curcumin
(20%, w/w) and (d) curcumin given in diet (1,000 ppm). Two-way ANOVA with Bonferroni posttest (P<0.5) was used to calculate statistically significant differences between the various
interventions.
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It is evident from Figure 4.9(a) that even the untreated animals exhibited significant
fluctuations in the baseline levels of both neutrophils and lymphocytes and their levels in
all the treatment groups were in baseline range of age-matched rats. However, since
both neutrophils and lymphocytes are markers of acute and chronic inflammation, mild
inflammatory reaction to these implantable fore ign bodies at least at the local site is
expected and is unavoidable as shown by Laurencin et al (140).
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Figure 4.9. Neutrophil and lymphocyte counts expressed on a logistic scale, measured after 1, 4,
12 and 90 days in blood of (a) untreated female ACI rats or (b) after subcutaneous implantation of
two 2-cm polymer alone blank implants (sham implants containing PCL:PEG , 65:35) , (c) implants
containing curcum in (20%, w/w) and (d) curcumin given in diet (1 ,000 ppm).

Evaluation of Local Implantation Sites
To further evaluate the effects of subcutaneous implants on the physical appearance or
motility of animals and/or at the local site, detailed pre-necroptic and histological
examination of the animals was carried out. All the animals were found to be physically
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healthy and active without any visual evidence of any kind of polymeric materialassociated toxicity even after 3 months of implantation of two 2-cm implants both with
and without curcumin. Grossly, local implantation sites grafted with either sham implants
(polymers alone) or curcumin implants appeared similar to the subcutaneous sites of
untreated animals with only slight but insignificant thickened areas at the implantation
sites. Normal hair growth without any redness or swelling was observed at the site of
implantation indicative of absence of any intra-cutaneous irritation or sensitization,
respectively, in animals. Representative microscopic tissue sections of local tissues
collected from around sham implants as well as around curcumin implants at 1, 4, 12, 25
and 90 days post-implantation are shown in Figure 4.10.

As is evident from Figure 4.10 (b, d, e, f, g), accumulation of mononuclear macrophages
at and around the implant site was the primary cellular reaction of the body towards
sham implants without any signs of contact cytotoxicity (as no necrotic sites were
observed during histological evaluation). Initially from 1-4 days (Figure 4.10 (b and d)),
local tissues around the sham (blank) implants showed a mild to moderate inflammatory
reaction with densely-packed macrophages in addition to neutrophils and fibroblasts. At
12 days (Figure 4.10 (c)), granulation tissue formation was observed with Significant
increase in capillaries with reactive endothelial cells. However by 25 days (Figure 4.10
(d)), severe granulomatous reaction was observed with heavy influx of epithelioid
histiocytes, multiple giant cells and fibroblasts resulting in a loosely formed granuloma by
90 days (Figure 4.10 (e)). Mild lymphocytic infiltration was observed at 25 days which did
not increase any further at 90 days. These observations were consistent with other
studies where implantation of hydrophobic materials like pel was found to preferentially
induce metabolically-active giant cells that are similar to surrounding macrophages
(141). The observed inflammatory reaction was restricted to the site of implantation and
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the surrounding layers of fibrous capsule around the implant, suggestive of only a local
inflammatory response without any apparent effects at other sites distant to the site of
implantation (142, 143). Furthermore, sections from liver collected at all-time points
showed no histological alterations again suggestive of absence of any significant
systemic toxicity.

Figure 4.10. Representative histology photographs of local implantation sites after different time
intervals. Panels a-c represent tissues from implantation sites of rats receiving no implant (a) ,
sham implant (blank implants without any curcumin) (b) or curcumin implant (c) at day 1. Panels
d, e, f, g represent local tissues at the site of sham implants after 4, 12, 25 and 90 days,
respectively. Panels h, i, j, k represent local tissues at the site of curcum in implants after 4, 12, 25
and 90 days, respectively. Tissues from untreated animals at all the time points were similar and
hence only a representative photograph is shown.

95

Initially, a similar reaction was observed with curcumin implants with mild to moderate
inflammatory response over a period of 4 days (Figure 4.10 (c and h)) which progressed
to granulation tissue formation at 12 days time period (Figure 4.10 (i)). Although a
granulomatous reaction progressing to a granuloma was observed at 25 and 90 days
(Figure 4.10 U and k)), it appears that the extent of lymphocytic infiltration was lower
than the sham implants. Curcumin, being a potent anti-oxidant and anti-inflammatory
agent, significantly reduced the intensity of granulomatous reaction. Considering that no
significant systemic toxic effects were observed during the time points investigated, and
no sign of a chronic reaction was observed at later time points, it appears that the
expected local reaction at implant site may not be a significant event. Further, curcumin
may be countering the local reaction caused by the polymeric materials and therefore,
no adverse chronic reaction can be anticipated. It may be noted that the neutrophil and
lymphocyte counts of rats that received curcumin implants were comparable to that of
untreated controls, particularly at the long term time point of 90 days, which reiterates
the local tissue findings.
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Conclusions
In summary, the subcutaneous polymeric implants investigated in this study were found
to have little or no systemic toxicity but an acute inflammatory reaction at local site of
implantation. Delivery of massive curcumin doses for a period of 90 days directly into the
systemic circulation did not elicit any significant changes in biochemical parameters of
liver and kidney function tests. Although, slight alterations in hematological parameters
especially neutrophils and lymphocytes were observed but their levels were well within
the normal physiological range of age-matched control animals. Over a period of 90
days, an acute local inflammatory reaction with presence of foreign body giant cells was
observed with sham implants which was significantly circumvented by curcumin implants
due to its anti-inflammatory properties. Absence of any significant chronic local or
systemic toxicity suggests testing of these implants in a clinical setting as a viable
alternative delivery system to administer curcumin (and other non-toxic natural products
with therapeutic activity) directly into the systemic circulation and to determine true
potential of curcumin as an anticancer/chemopreventive compound.
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CHAPTER V
CHEMOPREVENTIVE/CHEMOTHERAPEUTIC EFFICACY OF CURCUMIN
DELIVERED VIA POLYMERIC IMPLANTS

Rationale
Previous studies discussed in chapters II, III and IV showed that polymeric implants
provided controlled release of curcumin into the subcutaneous tissue from where it gets
absorbed into systemic circulation and gets distributed to various tissue sites. These
implants were found to maintain much higher plasma, liver and brain concentrations for
over a period of 3 months at -25-30 fold lower doses as compared to dietary
administration.

Furthermore, these implants were also found to be safe and

biocompatible when tested in ACI rats for a period of 3 months. Hematological
parameters (like WBCs, RBCs, platelets, basophils, eosinophils) and biochemical
parameters of liver (AST, ALP, AP, amylase) and kidney functions (Na+, K+, Ca2+,
creatinine,

BUN) were found to be unaltered by continuous direct systemic

administration of massive doses of curcumin by these implants. Therefore, this study
was designed to further evaluate these implants for their therapeutic efficacy against
estradiol (E2)-induced mammary carcinogenesis in ACI rats and was compared to
curcumin delivered via diet at a dose of 1,000 ppm. Furthermore, mechanistic aspects of
efficacy of curcumin inthis carcinogenesis model were explored to deduce curcumin's
mechanism of action against estrogen-induced mammary tumorigenesis.
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Materials and Methods
Materials
Medical grade poIY(E-caprolactone) (PCl) of 121,000 molecular weight (PCl) was
purchased from SurModics Pharmaceuticals (Birmingham, Al). Curcumin (C-3 complex)
extracted under GMP conditions (good manufacturing practices) for human use was a
generous gift from Sabinsa Corporation (East Windsor, NJ). Oichloromethane (OCM),
ethoxy resorufin and pyrene was purchased from Sigma-Aldrich (St. louis, MO).
Polyethylene glycol of 8,000 molecular weight (PEG) was purchased from Fisher
Scientific (Fair lawn, New Jersey), and ethanol from Pharmco-AAPER (louisville, KY).
Medical-grade silastic tubing (3.4 mm internal diameter) was purchased from Allied
Biomedical (Ventura, CA). All the materials were used as received without any further
analysis.

Methods
Preparation of Implants
Implants were prepared using solvent evaporation coupled with melt extrusion technique
as described previously in chapter II. Briefly, PCl and PEG (65:35) were dissolved in
OCM while curcumin at a drug load of 20% was dissolved in ethanol. The two solutions
were mixed together so as to prepare a homogenous solution followed by evaporation of
the solvents at 70 DC to form a molecular dispersion of drug in polymer. The semi-solid
mass obtained was further dried at 65 DC over night under vacuum to ensure complete
removal of OCM. The molten polymer material was then extruded into silastic tubes
(internal diameter 3.4 mm) at 65 DC and cut into desired lengths to form cylindrical
implants.
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Carcinogenesis Studies
Female ACI rats, 5-6 week-old were acclimated for 1 week under vivarium conditions,
followed by administration of AIN-93M control diet. After 2 weeks,

a 1.2-cm

silastic

implant containing 9 mg 1713-estradiol (E2) was grafted at the back of the rats as
described previously (119). All the interventions - curcumin diet (1,000 ppm), curcumin
implants (two 2-cm implants, 200 mg, 20% drug load) and blank implants (PCL:PEG
(65:35)) were started 4 days prior to E2 treatment. Animals were palpated every week
after 12 weeks for tumor appearance and tumor incidence was recorded in various
treatment groups. The experiment was terminated when tumor incidence was >80% in
E2-treated animals (after 6 months of estrogen treatment). Animals were euthanized by
asphyxiation under CO2 and all the animals were carefully examined for the presence of
mammary tumors to calculate tumor volume and multiplicity as described before (119).
Blood was collected by cardiac puncture and plasma was separated by centrifugation at
3,000g. Liver was cut into small pieces, snap frozen in liquid nitrogen in cryo-vials and
stored at -80 C. All the implants were also recovered, cleaned of tissue debris, dried
D

overnight under vacuum and stored for future use to measure residual drug load.

Residual Drug Determination
The rate of release of curcumin was determined by measuring the residual curcumin in
the implants recovered from animals as described in chapter III. Briefly, dried implants
were dissolved in DCM:ethanol (1:1) and the solution was first diluted (1 in 10) with
ethanol containing 20% DCM followed by in ethanol (1 in 40). Drug concentration was
measured in diluted solution spectrophotometrically at 430 nm and the rate of curcumin
release was calculated by subtracting the residual amount from initial amount per unit
time.
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Plasma Prolactin
Plasma prolactin was measured by using an EIA kit following manufacturer's protocol
(Alpco Immunoassays, Salem, NH).

Serum Estradiol (E2 )
Serum E2 was analyzed by using an estradiol II reagent kit purchased from Roche
Diagnostics, Inc. (Indianapolis, IN) following manufacturer's protocol.

Microsome Extraction
Liver (-100 mg) was homogenized in 0.25 M sucrose buffer (pH 7.4) at 3,000 rpm with a
polytron homogenizer. The homogenate was centrifuged at 3,000 g for 20 min at 4°C to
separate the nuclear content. The supernatant was further centrifuged at 11,000 g for 20
min at 4 °C to separate the mitochondria. The post-mitochondrial supernatant was then
transferred to ultracentrifuge tubes and centrifuged at 100,000 g for 1 h at 4 °C to
separate the microsomes. The pellet was suspended in 1 ml sucrose buffer, aliquoted
and stored at -80°C until use.

Cytochrome P450 Activities
Microsomal proteins were quantified using bicinchoninic acid (BCA) method (120) using
BCATM Protein Assay kit (Thermo Scientific, Rockford, IL). CYP1A and 1B1 activities
were determined by EROD assay with and without a selective CYP1 B1 inhibitor (pyrene)
(Ref). UGT activity was measured using UGT-GloTM Assay (Promega Corporation,
Madison, WI) following manufacturer's protocol and CYP3A4 activity was measured
using P450-GloTM CYP3A4 Assay with Luciferin-IPA ((Promega Corporation, Madison,
WI) following manufacturer's protocol but by replacing NADPH regenerating system with
NADPH (5 mM).
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Analysis of Plasma and Tissue Curcumin Levels
Plasma and tissues were analyzed for curcumin levels by HPLC as described in chapter
III. Briefly, plasma (1.5 ml) was taken from pooled plasma of all the animals and 200 III
of 0.5 M sodium acetate was added to reduce the pH to 5. Plasma was then extracted
thrice with 3 ml ethyl acetate. Ethyl acetate from 3 extractions was pooled together and
dried under vacuum. The dried residue was reconstituted in 100 III of acetonitrile (ACN),
half of which was injected to determine the plasma concentration. Similarly, liver tissue
(-500 mg) from each animal was homogenized in 3 ml PBS (pH 7.4) and 200 III of 0.5 M
sodium acetate was added. The homogenate was then extracted twice with 2 volumes of
ethyl acetate. After evaporation of ethyl acetate under vacuum, the residue was
reconstituted in 1 ml ACN. The ACN solution was filtered through 0.45 11 glass-microfiber
filter and evaporated again under vacuum. The residue was finally reconstituted in 100 III
ACN and half of it was analyzed by HPLC using Shimadzu liquid chromatography
system equipped with LC-10ADVP pump, RF-10AXL fluorescence detector and a
Shimadzu C 18 column of 5 11m particles (250 x 4.6 mm). The three curcuminoids were
separated using ACN and 1% citric acid (adjusted to pH 2.5) at a flow rate of 1 ml/min
with a gradient elution in which ACN concentration was increased from 0 to 30% in first 5
min, followed by an increase to 45% in next 5 to 20 min. ACN was then maintained at
this ratio till 36 min. Curcumin detection was achieved using 410 and 500 nm as
excitation

and

emission

maxima,

respectively,

in

the

fluorescence

detector.

Quantification of curcumin levels was done by using calibration curves prepared from
pure standards of each individual curcuminoid.
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Statistical Analysis
Generalized linear model approach was used to analyze the group effect of tumor
volume, cube root tumor volume and tumor number using SAS version 9.2 software. The
p value of Shapiro- Wilk normality test for tumor volume and for cube root tumor volume
was found to be <0.0001 and 0.7505, respectively. Hence cube root tumor volume was
considered to be distributed normally and was used to calculate statistically significant
differences in tumor volumes with different interventions.
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Results and Discussion
In our previous studies we showed that curcumin release from implants follow biphasic
release pattern characterized by an initial burst release phase ranging from 7-10 days,
followed by a more controlled release phase (chapter II). As shown earlier, these
implants with PEG (35% w/w) released -1.8 mg of curcumin on first day that decreased
with time and released -10.9 mg of curcumin over a period of 25 days with an average
release of -436 Ilg/day from each implant (Figure 5.1). The release dropped significantly
by 90 days with only 19 mg cumulative curcumin being released into the systemic
circulation in 3 months at a rate of -126 Ilg/day/implant between 25-90 days. Since the
release was expected to drop further, implants were replaced with new implants at -138
days when average daily drug release dropped to -95 Ilg/day/implant. Insertion of new
implants not only provided a burst release of curcumin at the tumor initiation stage but
also provided a higher daily drug release for the rest of the period to achieve maximum
chemopreventive and chemotherapeutic activities of curcumin during the tumor initiation
and promotion phases. The average daily drug release from new implants was found to
be around 357 Ilg/day/implant from 138 to 180 days, with a total release of 36.1 mg from
both old and new implants (Figure 5.1).
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Figure 5.1. In vivo (daily and cumulative) release of curcumin from a 2-cm implant (200 mg, 20%
drug load) recovered from animals after specific time intervals over a period of 6 months (n=3,
±SD).

Tumor Incidence
Tumor incidence was measured by palpating the mammary tissue pad of animals every
week for appearance of any tumors from 12-14 weeks of E2 treatment. The first tumor in
all the E2 treated groups appeared between 95-110 days (Figure 5.2). Although
curcumin delivered via diet did not affect the appearance of first tumor (95 days),
curcumin implants slightly delayed the tumors by 7 days. However, subsequent
appearance of tumors was similar to control treatments suggesting insufficient doses of
curcumin reaching into the systemic circulation. The implants were, therefore, changed
at -135-140 days when -20% animals in each group developed tumors to provide a
burst release of curcumin at the peak tumor initiation stage.
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Figure 5.2. Mammary tumor incidence in female ACI rats treated with a silastic E2 implant along
with either two blank polymeric implants (2 cm, no drug), or two curcumin implants (2 cm , 20%
drug load) or curcumin diet (1,000 ppm) for over a period of 6 months.

As is evident from Figure 5.2 , burst release of curcumin provided by new implants at the
time of initiation almost completely stopped the appearance of any new tumors for at
least 3 weeks and the delay was maintained during the rest of the period. Analysis of
average tumor volume per tumor (Table 5.1) and palpable tumor volume with time
(Figure 5.3) further showed that after a delay of 3 weeks, the tumor growth was similar to
the control groups and curcumin implants did not have any effect on growth of tumors.
This observation suggests that probably curcumin had only chemopreventive activity and
no chemotherapeutic potential at least in this model.
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Figure 5.3. Palpable tumor growth kinetics of animals treated with E2 along with sham implants or
with curcumin implants.

With an aim to further substantiate these findings, we also measured serum prolactin
levels at all the 3 time points. Prolactin is a pituitary hormone released during late
pregnancy and lactation by presence of high E2 concentrations in systemic circulation. It
has also been proposed that mammary tissues produce prolactin during carcinogenesis
that acts as an autocrine and paracrine growth factor for mammary tissue proliferation
(144) . Moreover, prolactin release from pituitary homografts have been shown to
increase mammary tumor incidence in ovariectomized rats (145), suggesting a mitogenic
role of prolactin in promoting the growth of already transformed normal and preneoplastic cells (144). It was found that at 3 weeks, curcumin implants significantly
reduced plasma prolactin levels as compared to blank implants; however were
ineffective at 3 months time point (Figure 5.4). Once the implants were replaced with
new implants, the burst release of high curcumin doses again inhibited the E2 mediated
prolactin release at 6 months of E2 treatment. The diet on the other hand , was ineffective
at all the time points studied. These results suggest that release of bolus doses of
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curcumin at 3 weeks from initial implants and at 6 months (from new implants changed
after 135 days) significantly reduced the plasma prolactin levels.
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Figure 5.5. Mammary tumor volume in female ACI rats treated with a silastic E2 implant along
with either two blank polymeric implants (2 cm , no drug) , or two curcumin implants (2 cm, 20%
drug load) or curcumin diet (1000 ppm) for over a period of 6 months.

At the termination of the study, all tumors were measured to determine the average
tumor volume and are shown in table 5.1 and Figure 5.5. Curcumin diet at a dose of
1,000 ppm was found to be ineffective as compared to E2 treated group. However,
curcumin implants were found to significantly reduce the tumor volume by -35% as
compared to blank implants with E2 treatment group. Since, curcumin implants as such
were not found to have any chemotherapeutic activity in this model; it appears that this
reduction in tumor volume was due to 3 weeks delay in tumor appearance after the
change of implants. Analysis of average number of tumors observed per animal (tumor
multiplicity) also supported these observations (Figure 5.6 and table 5.1). Curcumin
implants were highly effective in reducing the tumor multiplicity by 70% (2±1 versus 5±2)
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as compared to blank implants; curcumin diet, however, was ineffective when compared
with E2 alone treatment group.
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Table 5.1.
Tumor volume and respective tumor multiplicities of animals treated with Eg implants and either with control diet, two 2-cm
blank implants, two 2-cm curcumin implants or with curcumin diet (1,000 ppm).

Animal
#

-

......

......

tv

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Mean

SO

E2 treatment
Tot Tum.
# of
Volume!
Vol.
tumor
(mm 3)
Tumors ..uif!1m3)

35
1954
1157
863
88
66
20
349
734
113
11 08
423
609
431
1403
737
1774
437
90
466
643
579

4
15
6
4
3
1
3
5
4
5
3
5
5
4
6
4
5
4
6
7
5
3

9
130
193
216
29
66
7
70
184
23
369
85
122
108
234
184
355
109
15
67
129
106

Sham Imp + E2
Tot Tum.
# of
Volume!
Vol.
tumor
(mm3L_ Tumors
(mm3)

100
166
297
436
470
208
57
241
325
14
335
523
354
429
301
345
177
184
433
201
280
141

3
7
2
1
4
5
3
11
4
4
4
6
13
5
8
1
5
6
3
7
5
3

33
24
149
436
118
42
19
22
81
4
84
87
27
86
38
345
35
31
144
29
92
111

*Removed from calculations as an outlier using mean±3 S.D. relation

Cure Diet + E2
Tot Tum.
# of
Volume!
Vol.
tumor
(mm3)
Tumors
(mm3)

Cure Imp + E2
Tot Tum.
# of
Volume!
Vol.
tumor
(mm3)
Tumors
(mm3)

478
147
152
1111
270
286
273
119
97
113
462
1127
233
166
56
624
165

6
4
6
6
3
2
3
7
7
7
2
2
10
6
4
13
11

80
37
25
185
90
143
91
17
14
16
231
564*
23
28
14
48
15

457
631
170
208
222
41
29
17
22
406
50
290
34
0

3
1
1
3
4
2
2
1
1
2
1
5
2
0

152
631*
170
69
56
21
15
17
22
203
50
58
17
0

346
328

6
3

66
67

184
198

2
1

65
67

These results are consistent with other studies where it has been shown in DMBA
(Dimethyl benz[a]anthracene) induced mammary cancer model that many potent
chemopreventives like indole-3-carbinol (1-3C) exert maximum effect when given during
pre-initiation stage (146, 147) and are more effective in reducing tumor multiplicity than
tumor volume (148). This significant reduction in tumor multiplicity, therefore, again
suggests that high bolus doses of curcumin delivered by new implants at the time of
tumor

initiation

exerted

maximum

chemopreventive

activity

and

probably

no

chemotherapeutic activity. It has also been shown in these studies that such a potent
inhibition of tumor multiplicity is often due to changes in hepatic carcinogen metabolizing
enzymes that are preferentially induced or inhibited to decrease the formation of reactive
carcinogen metabolites and to enhance carcinogen detoxification (148). This favorable
alteration in carcinogen metabolism, then ultimately results in reduced genetic mutations
blunting the neoplastic trigger.

Previous mechanistic studies of estrogen induced mammary carcinogenesis have shown
that E2 mediated mammary carcinogenesis is a 2-step process (149) characterized by
an initial initiation phase where highly reactive carcinogenic E2 metabolites like 4hydroxy estradiol (4-E2) binds with DNA leading to genetic mutations that result in
neoplastic transformation of mammary cells (Figure 5.7). Initiation phase is followed by
tumor promotion phase which is mediated by hormonal activity of E2 and 4-E2 via their
interaction with estrogen receptor a (ERa) and subsequent activation of proliferation
signaling (150). Since curcumin implants were found to exert their effect only during the
initiation stages, it appears that favorable alteration of E2 metabolizing cytochromes
played a significant role in their efficacy. E2 is known to get metabolized by 3 distinct
cytochromes giving di'fferent metabolites. E2 metabolism by CYP1 B1 results in formation
of 4-0H (4-E2) metabolites that are potent carcinogens and are initiators of
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carcinogenesis cascade. On the other hand, E2 metabolism by CYP1A (1A1 and 1A2)
and CYP3A4 are true detoxification pathways forming 2-0H (2-E2) metabolite
(anticarcinogenic) and to some extent 16-0H (16-E2) metabolite (151). Since previous
studies showed that modulation of hepatic xenobiotic metabolizing enzymes affects
tumor initiation and tumor incidence (146, 148), we extracted hepatic microsomes and
analyzed their CYP1 81 , CYP1 A (1 A 1 and 1A2) and CYP3A4 activities (Figure 5.8a, b
and c) .
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Figure 5.7. Mechanistic overview of cytochrome P450-mediated bio-activation of Estradiol to
initiate carcinogenesis and to promote proliferation (modified from (152)) .

CYP181 activity was found to exhibit time dependent kinetics with slow sustained E2
treatment by silastic implants (Figure 5.8a) . Enzyme activity increased significantly after
3 weeks of E2 treatment which decreased to even less than untreated controls by 3
months treatment. Although , at 6 months again an increased CYP181 activity was
observed but the increase was insignificant due to wide variation in untreated control

114

and E2 treated animals. Similarly, both curcumin diet as well as curcumin implants, in the
absence of E2, increased 1B1 activity both at 3 weeks and 6 months as compared to
untreated control animals. However in presence of E2 curcumin diet either showed no
effect on CYP1 B1 activity (at 3 weeks and 6 months) or increased it significantly (at 3
months). Curcumin implants, on the other side, significantly reduced CYP1 B1 activity at
all the time points in presence of E2. Since, CYP1 B1 is known to be the major xenobiotic
metabolizing enzyme responsible for formation of 4-E2' a potent carcinogenic E2
metabolite, inhibition of CYP1 B1 activity by curcumin implants can result in reduced
formation of reactive carcinogenic E2 metabolites delaying tumor initiation and blunting
tumor mUltiplicity.

CYP1A1 activity also showed time dependent and exposure dependent kinetics with E2
treatment (Figure 5.8b). Enzyme activity was found to increase both at 3 weeks (though
insignificantly) and 6 months (highly significantly) but significantly decreased at 3 months
of E2 treatment as compared to untreated control animals. Both curcumin diet as well as
curcumin implants increased CYP1 A 1 activity also as compared to untreated animals in
absence of E2. However, in presence of E2, curcumin diet did not have any effect on
CYP1A1 activity at 3 weeks but increased significantly at both 3 and 6 months of E2
treatment. Curcumin implants on the other hand, significantly increased CYP1 A 1 activity
at 3 weeks as compared to animals with blank implants and E2 treatment.
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Figure 5.B. (a) CYP P450 181 , (b) 1A (1A1 and 1A2) (c) and 3A4 activities of hepatic mierosomes
isolated from female ACI rats treated with or without a silastie E2 implant along with either two
blank polymeric implants (2 em, no drug) , or two eurcumin implants (2 em , 20% drug load) or
eureumin diet (1 ,000 ppm) for over a period of 3 weeks, 3 months and 6 months.

CYP3A4 activity on treatment with E2 , significantly decreased both at 3 weeks and 3
months time point as compared to untreated animals (Figure 5.8c) . Although, activity
increased slightly at 6 months, due to wide variation in CYP3A4 activity in untreated
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animals, significance was not achieved. Curcumin diet was not found to exert any effect
on CYP3A4 activity with or without E2 but curcumin implants significantly increased
CYP3A4 activity at all the time points in absence of E2. However, in presence of E2 an
increased activity was observed only at 3 and 6 months treatment when much higher
curcumin concentrations were administered from new implants (300-400 Ilg/day/implant)
compared to 3 months when release was low (-120 Ilg/day/implant).

Since, CYP3A4 is a major xenobiotic metabolizing enzyme, an increase in its activity
means increased metabolism and excretion of subcutaneously delivered E2 from the
systemic circulation as non-carcinogenic metabolites and hence better therapeutic
efficacy. Therefore, to gain further insights into the metabolism enhancing effects of
curcumin, especially when delivered via implants, we measured E2 concentration in
serum both after 3 weeks and 3 months as maximum alteration in enzyme activities was
observed at these time points (Figure 5.9). As is evident from the Figure 5.8,
administration of E2 by silastic implants significantly increased serum E2 concentration at
all the time points as compared to untreated control animals. Curcumin diet and implants
both did not have any effect on endogenous levels of E2 and serum estradiol
concentrations were similar to untreated control animals in absence of silastic E2
implants. However, in presence of extraneous E2, serum E2 concentration was found to
be low with curcumin implants both at 3 weeks and 3 months, although the decrease
was significant only at 3 months. Dietary curcumin, however; was ineffective.
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Figure 5.9. Serum estradiol (E 2) levels of female ACI rats treated with or without a silastie E2
implant along with either two blank polymeric implants (2 em , no drug) , or two eureumin implants
(2 em , 20% drug load) or eureumin diet (1 ,000 ppm) for over a period of 3 weeks and 3 Months.

Since, only curcumin delivered by implants was able to modulate E2 metabolism as
compared to dietary route , we further measured curcumin levels both in plasma as well
as in liver to see if these differences in activities by both routes were due to differences
in curcumin concentrations (Figure 5.10). Curcumin was undetectable in plasma at all
the time points when given by dietary route, consistent with other studies but was found
to be 1.1, 0.3 and 0.6 nM in the case of curcumin implants in the absence of E2 • On the
other hand, significantly higher concentrations of curcumin were observed in presence of
extraneous E2 as compared to untreated E2 animals. In presence of silastic E2 implants
curcumin was detected at levels of 1.4 nM at both 3 weeks and 3 months' time point and
0.9 nM after 6 months of dietary administration and was 2.4, 1.9 and 0.9 nM after 3
weeks, 3 months and 6 months of E2 treatment with curcumin implants. Although the
plasma levels at 180 days are not significantly higher as compared to 90 days, it is to be
noted that the implants were changed at 138 days, at which point the burst release
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phenomenon would have occurred, to provide much higher plasma concentrations
resulting in observed delay in tumor incidence and reduction in tumor mUltiplicity.
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Figure 5.10. Plasma (a) and liver (b) curcumin concentration of female ACI rats treated with or
without a silastic E2 implant along with either two blank polymeric implants (2 cm , no drug) , or two
curcumin implants (2 cm , 20% drug load) or curcumin diet (1 ,000 ppm) for over a period of 3
weeks, 3 Months and 6 months.

Analysis of liver curcumin concentration also revealed a similar trend. Although curcumin
was not found in plasma after dietary administration, it was found in liver tissue at all the
time points even in absence of E2 treatment. In absence of E2, - 16.6±11.7 ng/g and 9±1
ng/g curcumin was observed by implant and dietary route , respectively, after 3 weeks.
Although , almost similar levels of curcumin were observed at 3 months (9±3 ng/g) and 6
months (9±1 ng/g) by curcumin diet, with implants, the levels decreased slightly from
16.6 to 8.9±3 ng/g after 3 months and increased again to 13.4±8 ng/g at 6 months
treatment after replacing the implants at 135 days. As was in plasma, significantly
increased curcumin concentrations were observed in liver tissue in presence of E2
implants. Curcumin concentrations of 40±21 ng/g , 32±12 ng/g and 21 ±9 ng/g were
observed by dietary route after 3 weeks, 3 months and 6 months of E2 treatment. Much
higher curcumin concentrations of 61 ±28 ng/g, 35±6 ng/g and 32±16 ng/g tissue were
observed by implant route after 3 weeks, 3 months and 6 months of E2 treatment at

119

around 11-, 23- and 24-fold lower doses, respectively, compared to the dietary doses.
These observations suggest that not only curcumin (at least via implant route) altered
the hepatic metabolism of E2 but presence of E2 also altered curcuminmetabolism to a
significant extent. Curcumin is known to get metabolized by both CYP3A4 (122) and
UGT (12) and it is evident from Figure 5.7c that administration of E2 by silastic implants
significantly decreased CYP3A4 activity at initial time points. Measurement of UGT
activity also showed a similar decrease (Figure 5.11) both at 3 weeks and 3 months time
point suggestive of decreased hepatic curcumin metabolism.
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Figure 5.11. UGT activity of hepatic microsomes isolated from female ACI rats treated with or
without a silastic E2 implant along with either two blank polymeric implants (2 cm, no drug) , or two
curcumin implants (2 cm , 20% drug load) or curcumin diet (1,000 ppm) for over a period of 3
weeks , 3 months and 6 months.
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Conclusions
Curcumin implants showed diffusion-mediated biphasic release kinetics both under in
vitro as well as under in vivo conditions with a 2-fold higher drug release in vivo as
compared to in vitro. Curcumin implants were able to significantly reduce the plasma
prolactin levels as well as estrogen induced mammary tumor burden and tumor
multiplicity as compared to curcumin diet suggestive of better chemopreventive
outcomes when delivered systemically. The enhanced chemopreventive efficacy of
curcumin delivered

vit~

implants was found to be due to favorable modulation of hepatic

CYPs. CYP1 81 activity was found to be significantly reduced by curcumin implants while
was increased by curcumin diet. CYP1 A and CYP3A4 activities were found to be
increased significantly by implant route. Taken together, these data are suggestive of
increased metabolism of estradiol to carcinogenic metabolites by curcumin diet and to
non-carcinogenic metabolites by curcumin implants. This differential activity was found
to be due to different liver and plasma concentrations from both the routes. Curcumin
concentration was found to be much higher both in plasma as well as in liver when
delivered via implants as compared to curcumin diet.

121

CHAPTER VI
SUMMARY AND FUTURE PERSPECTIVES

Polymeric implants of curcumin were found to release controlled amounts of curcumin
directly into the systemic circulation. The implants were found to be stable during the
formulation, storage as well as under in vivo conditions with predictable curcumin
release for up to 16 months. Plasma and brain curcumin levels were found to be
significantly higher, while liver concentrations were similar, by implant delivery system
compared with the dietary route despite 25-30 fold higher doses of curcumin
administered orally after 3 months. Furthermore, curcumin levels achieved in liver were
sufficient to alter the expression/activity of hepatic cytochromes. These Implants with
chronic administration of curcumin were found to be safe and biocompatible with respect
to both chronic administration of curcumin as well as to implant formulation. Curcumin
doses administered by implant route were found to effectively inhibit estrogen- mediated
mammary carcinogenesis in female ACI rats via favorable modulation of 17J3-estradiolmetabolizing enzymes to produce non-carcinogenic metabolites. Furthermore, curcumin
was not found to have any chemotherapeutic potential at these doses in this model and
possessed only chemopreventive activity.

These studies showed that polymeric implants are a viable alternative for less
bioavailable chemopreventive compounds like curcumin and can maintain controlled
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drug levels ranging from months to years by releasing constant amounts of drug per unit
time. Furthermore, this drug-delivery system can be tailored to a host of other
chemopreventive and therapeutic agents thus increasing their bioavailability and
reducing their effective doses as compared to traditional dietary administration. This
delivery systems can also be used to screen minor phytochemicals or synthetic drugs
which otherwise do not undergo activity assessment due to insufficient quantities
available at the initial drug discovery stages.

Future Perspectives
../ Increase drug release and rapid implant degradation: Use of alternate polymers
with short half-life like PLGA can be explored to enhance the drug release with
rapid rate of polymer degradation .
../ These implants need to be tested using other carcinogen-induced carcinogenesis
animal models or in some transgenic models with or without various
chemotherapeutic compounds to determine their true potential.
../ These implants could also be tested in high risk breast cancer patients so as to
determine their translational potential.
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LIST OF ABBREVIATIONS
Imp

Implant

Curc

Curcumin

ECF

Extracellular Fluid

PCl

poIY(E-caprolactone)

P-15

POIY(E-caprolactone), 15,000 molecular weight

P-65

POIY(E-caprolactone), 65,000 molecular weight

DCM

Dich loromethane

ACN

Acetonitrile

PBS

Phosphate-buffered- saline

BCS

Bovine calf serum

SEM

Scanning electron microscopy

FT-IR

Fourier transform infra red spectroscopy

pXRD

Powder X-ray diffraction

DSC

Differential Scanning Calorimetry

HPCD

2-hydroxy propyl f3-cyclodextrin

PEG

Polyethylene glycol, 8,000 molecular weight

lIP

Intraperitoneal

IN

Intravenous

SIC

Subcutaneous

ACI

Augustus Copenhagen Irish

CYP1A1

Cytochrome P4501A1

CYP1B1

Cytochrome P4501A1

CYP3A4

Cytochrome P4501 A 1

GSTM

Glutathione S- transferase (1-1)

UGT

UDP-glucuronosyltransferase

EROD

Ethoxy resorufin deethylase

E2

17 f3-Estradiol

2-E2

2-hydroxy estradiol

4-E2

4-hydroxy estradiol

16-E2

16-hydroxy estradiol
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